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Escherichia coli is a common host for recombinant protein production for 
biotechnology applications. Secretion of recombinant proteins to the extracellular and 
periplasmic space has the potential to reduce protein aggregation and to simplify 
downstream purification. A directed mutagenesis approach (specifically changing 
abundant codons to synonymous rare codons in a specific region) previously resulted 
in an eight-fold improvement in active hemolysin (HlyA) secretion. Also, synonymous 
codon substitutions have been shown to alter protein folding and function; however 
this mechanism is not well understood. In the first part of this study, a series of 
experiments have been described to study the effect of synonymous rare codon 
clusters on protein folding and secretion via multiple pathways in E. coli. Significant 
improvement in extracellular and periplasmic secretion of various recombinant 
proteins was observed by synonymous rare codon engineering. The analyses also 
revealed that synonymous rare codon cluster at specific sites of the target gene can 
alter polypeptide folding and activity by modulating the interactions of polypeptide 
with molecular chaperones. The study provides an experimental toolkit to enhance 
recombinant protein secretion in E. coli and offer insights into the effect of silent 
mutations on protein folding. The second part of the thesis includes genome sequence 
analysis of a derivative hypersecreter E. coli strain (B41), created previously by 
 random mutagenesis, and the parent strain using a ‘next-generation’ sequencing 
technology. Mutational profiling revealed a single nucleotide polymorphism (G  T) 
in the B41 genome, which results in premature translation termination of a 
transcription factor, RutR. Comparative mRNA expression analysis revealed that 
absence of RutR coordinates a decrease in the expression of tRNA-synthetases and 
some amino acid transporter genes, suggesting that the absence of RutR may result in 
slower translation rate. The work presents a single gene target to enhance extracellular 
secretion via the Type-I pathway and highlight the potential of new high-throughput 
massively parallel sequencing technologies to characterize selected mutants for strain 
improvement. 
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CHAPTER 1 
INTRODUCTION 
   
1.1 Background and Motivation 
Recombinant DNA technology is used for the production of therapeutic or industrially 
relevant proteins in bacterial, yeast and other cell types. The annual global market for 
biopharmaceuticals is estimated at more than $33 billion and products derived from 
Escherichia coli  represent nearly 30 % all the biopharmaceuticals made in the US and 
EU [1]. As listed in Table 1.1, a number of important biopharmaceuticals are produced 
in E. coli, including vaccines, interleukins, and hormones [1]. Thus, improvements in 
the production of heterologous protein in E. coli can have enormous economic impact. 
E. coli has become the host organism of choice for the expression of many 
heterologous genes, primarily because of the ease with which the organism may be 
genetically manipulated. Compared to other organisms, recombinant protein 
production in E. coli is simpler due to high growth rate, simple nutritional 
requirements, genetic stability, and ease of product purification. E. coli can be used in 
a wide range of applications, particularly where post-translational modifications are 
not required for the functions of target proteins. Furthermore, this organism has the 
ability to overexpress recombinant proteins to at least 20% of total cellular protein and 
to export them from the inside of the cell (cytoplasm) to the outside (periplasm or 
extracellular medium) [2]. 
 
Expression of heterologous proteins in E. coli can be divided into two major 
categories based on the final destination of the protein being processed. Heterologous 
proteins may be expressed to accumulate in the cytoplasm (intracellular expression), 
or the protein may be exported into the periplasmic space or culture media via  
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Table 1.1. Biopharmaceuticals that are produced in Escherichia coli and have been 
approved by FDA in 2006. Six categories of products and their therapeutic indication 
are shown. 
Adjunct to surgery for subsequent 
tumor removal
Monoclonal Antibody based products
(Recombinant tumor Necrosis Factor- α)
Lyme disease vaccineRecombinant vaccines
Hepatitis C, Multiple sclerosis, 
Rheumatoid arthritis, 
Chemotherapy induced 
thrombocytopenia
Recombinant interferons and interleukins 
(Interferon-α, Interferon-β, Interleukin-1, 
Interleukin-11, Interleukin-12)
Autologous bone marrow 
transplantation
Recombinant hematopoietic growth factors 
(GM-CSF)
Diabetes mellitus, growth 
hormone deficiency in children, 
Osteoporosis 
Recombinant hormones (Insulin, Human 
growth hormone)
Acute myocardial infarction Recombinant anticoagulants 
(Tissue plasminogen factor )
Therapeutic IndicationProduct
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translocation pathways (secretion). Intracellular expression of proteins in the 
cytoplasm often results in the formation of inclusion bodies, which are unwanted  
protein aggregates [3]. These aggregates are not functional and are often difficult to 
process, thereby increasing production cost and reducing yield. Secretion of 
heterologous proteins in the periplasm can simplify purification processes, but often 
results in production bottlenecks because the translocation pathways are difficult to 
sustain at high levels of transport and the mechanisms of export are not well 
understood. The periplasm of E. coli contains fewer protein species and proteases than 
the cytosol, reducing the complexity of the initial mixture of contaminants. However 
inclusion bodies may also form in the periplasm as a result of high concentration of 
recombinant proteins [4].  
 
From a biotechnology perspective, heterologous protein secretion into the extracellular 
medium is desirable because concentration of the protein of interest remains low, thus 
minimizing protein aggregation. Additionally, the extracellular environment can be 
controlled to provide optimal osmolarity and pH for protein folding and stability. 
However, there have been few successful attempts to secrete proteins into the 
extracellular medium, some of which have been reported in [2] and [5-9]. Efforts to 
alleviate bottlenecks in secretion pathways via metabolic engineering do not often 
produce the desired phenotype, primarily because of the low efficiency and high 
specificity of most secretion systems and an incomplete understanding of their 
mechanisms. While E. coli exports several types of proteins to the periplasm, secretion 
pathways to the extracellular medium are often specific for only a few proteins. 
Understanding and controlling translocation mechanisms enables better control over 
the secretion systems for the production of recombinant proteins.  
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Previous studies have established that the protein synthesis rate is an important 
consideration for secretion efficiency [8, 10]. Of the number of factors that can affect 
protein synthesis rate; plasmid copy number, translation initiation region, and 
differences in codon usage have been studied in greater details in the context of 
secretion. Plasmid copy number can affect the number of available ribosomes for 
translation and studies have shown that E. coli transformed with plasmids with 
different copy numbers exhibited altered export of human proinsulin to the periplasm 
[11]. It was found that the use of plasmids of moderate copy number (15-60) versus 
low copy number (11) increased export, but this study did not include a high copy 
number plasmid. Studies on the export of recombinant proteins to the periplasm [10] 
revealed that a change in the sequence of the translation initiation region (TIR) affects 
the rate of translocation by the Sec pathway. However, an increase in protein 
expression levels brought about by differences in the strength of TIR did not 
uniformly increase the amount of protein secreted. Rather, the optimal TIR (and 
presumably, expression level) varied for each protein tested [10]. The investigators 
speculated that the change to the first few codons in the gene sequence that were made 
might affect the structure of the mRNA resulting in enhanced binding and translation 
by the smaller ribosomal subunit. Nevertheless, this study demonstrated that an 
optimum translational level exists to achieve high-level secretion of each heterologous 
protein, and outside of this optimum level, secretion levels drop off significantly.  
 
Differences in codon usage between the source organism and the production host have 
also been observed to affect the translation rate of recombinant proteins because codon 
usage directly correlates with the abundance of codon-specific tRNAs available within 
the cell [12]. Generally, a synonymous substitution of the codons in the gene of 
interest to more commonly used codons in the host cell alleviates this problem [13]. 
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Recent studies have demonstrated that a decrease in the translation rate of HlyA leads 
to an enhanced secretion capability via Type-1 secretion machinery [8]. In particular 
an E. coli W3110 strain, designated as hly-slow, was engineered to have a predicted 
37% decrease in protein production rate. This strain showed an eight-fold 
improvement in hemolysin secretion as compared to the control strain, designated as 
Hly-parent. The relative decrease in the translation rate was achieved by changing five 
of the adjacent codons to rare codons in a specific region of hlyA gene but without 
altering the amino acid sequence. Rare codons are defined as those codons whose 
corresponding tRNA concentration is less than 1% of the total tRNA concentration (as 
tabulated in [24]).  The use of rare codons in a gene has been shown to reduce the 
translation rate because the number of available aminoacyl-tRNAs is limited [14].  
 
Studies have also shown that synonymous codon substitutions can change protein 
structure and function, indicating that protein structure is DNA sequence dependent. 
Synonymous codon substitutions that change codon usage frequencies from infrequent 
to frequent usage in regions of slow mRNA translation can deleteriously affect 
enzyme activity [15]. Conversely, synonymous substitutions that introduce rare 
codons into regions predicted to contain high frequency codons show altered substrate 
specificities [16]. Thus, contrary to conventional thinking, synonymous codon 
substitutions may not always be silent; changing codon usage frequency affects 
protein structure and function, and the frequency with which codons are used imparts 
vital information for the development of secondary and tertiary protein structure. 
Species-specific disparities in codon usage are frequently cited as the cause for 
failures in recombinant gene expression by heterologous expression hosts. Such 
failures include lack of expression, or the expression of protein that is non-functional 
or insoluble, or protein that is truncated because of proteolysis or premature 
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termination of translation [17–19]. All but the last of these failures are attributable to 
misfolded protein. In E. coli, as well as eukaryotic species, nascent proteins fold co-
translationally within the ribosomal tunnel, which is both a protective environment 
within which secondary structure begins to form [20–22], and a dynamic environment 
that influences nascent protein structure [23–26]. Within the ribosomal tunnel, subtle 
variations in the rate of mRNA translation may play a key role in developing 
secondary structure in the nascent protein. Translation is not a steady state process, 
rather it occurs in pulses, as can be observed from ribosomal pausing [27] and even 
ribosome stacking, on specific stretches of mRNA [28]; these temporal changes in 
translational rate have been shown to depend on relative tRNA levels [29].  
 
tRNA isoacceptor abundance and isoacceptor usage frequencies are directly related for 
naturally occurring proteins from E. coli as well as from other organisms [30–33], and 
there is evidence that protein secondary structure is related to tRNA usage frequencies 
[34], although this concept is controversial [35]. Comparative analysis of E. coli gene 
sequences and their respective protein structures show that amino acid sequences 
encoded by more frequently used codons are associated with highly ordered structural 
elements such as alpha helices, while sequences containing clusters of less frequently 
used codons tend to be associated with the protein domain boundaries (link/end 
segments) that separate such elements [36]. That analysis also showed that the 
link/end segments tend to be populated with amino acids that have bulky hydrophobic 
side chains or side chains that can hydrogen bond to the peptide backbone. When such 
residues appear in link/end segments, they tend to be encoded by infrequently-used 
codons. Therefore, the positioning of clusters of relatively high and low abundance 
codons on mRNA transcripts may be a purposeful rather than a random occurrence 
[37]. The idea that link/end segments, which separate elements of higher order protein 
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structure, are encoded by clusters of low-usage frequency codons leads to the 
hypothesis that slow translational progression (i.e., ‘‘pausing’’) through such regions 
of mRNA would allow the preceding nascent structural element to fold, at least 
partially, within the environment of the ribosomal tunnel prior to initiation of synthesis 
of the next structural element [38]. Such a temporal control mechanism would 
minimize the interaction between partially folded nascent polypeptides in the cytosol, 
an event which can lead to degradation, or aggregation and precipitation. 
 
From a system’s perspective, the study of secretion systems has focused primarily on 
the proteins involved in secretion machinery, while less is known about the regulation 
of associated pathways, which may be crucial in alleviating bottlenecks in the process. 
The availability of genome sequence information has ushered in a new era of biology 
focused at the organism-wide level. Application of genomic and proteomic 
technologies has generated a lot of interest in the bioprocess development, because 
these tools provide molecular level details and aid in exploration of cellular functions 
to aid strain improvement [39]. Powerful techniques, such as cDNA microarrays and 
two-dimensional electrophoresis coupled with mass spectrometry, can provide 
interesting gene and protein expression changes which can give important clues to 
understand cellular phenotype. However, these tools do not provide the sequence 
information of the changes in the organism’s genome which likely induce the 
observed expression changes.  
 
DNAsequencing is a central technology in our understanding of the molecular basis of 
many fundamental problems of biology. The Human Genome Project and the 
resequencing of selected regions of the human genome in disease association studies 
have contributed to a refined understanding of the molecular basis of many 
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diseasesThe so-called ‘next-generation’ sequencing technologies like Illumina 
Genome Analyzer, 454 Roche, Applied Biosystems SOLIDTM offer dramatic cost 
reductions and throughput increases and have revolutionized the drug discovery and 
pharmaceutical development process. These new technologies are being used 
extensively to understand disease association, drug resistance, biomarkers, and 
develop molecular diagnostics [40-43]. From a biotechnology standpoint, the use of 
these technologies can accelerate strain improvement because traditional genetic tools 
cannot easily identify the mutations related to interesting phenotypes, generated by 
genetic mutational studies, adaptive evolution, and phenotypic screening. Moreover, 
these technologies can be used in tandem with “-omics” tools to gain insights into 
specific gene functions and provide interesting targets for metabolic engineering.  
 
1.2 Project Goals 
The overarching objective of this project is to understand and develop methods to 
engineer an enhanced capability of E. coli cells to secrete active recombinant proteins. 
The main sub-goals of this work are as follows: 
1. Understand the effect of synonymous mutations on the secretion of 
recombinant proteins via the Type-I pathway and other secretion pathways. 
This goal is based on previous observations [8,45]. 
2. Utilize the secretion pathways and their quality control mechanisms to 
explore the effect of synonymous rare codon clusters on protein folding 
and interactions of polypeptide with molecular chaperones. This goal is 
based on the idea that slower translation progression through the rare codon 
cluster can affect the folding of the preceding nascent structural element or 
its interaction with accessory proteins, within the environment of the 
ribosome tunnel [44]. 
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3. Characterize a selected hypersecreter E. coli mutant strain at the genome 
sequence level using new genome sequencing technologies. This goal is 
based on our previous observation [8] and aims to discover novel metabolic 
targets for hypersecretion of recombinant proteins in E. coli.  
 
1.3 Scope of Work 
This dissertation first provides some background information about different systems 
for export to the periplasm and extracellular medium employed by E. coli (Chapter 2).  
These diverse pathways are important for both biotechnology applications and the 
study of infectious diseases. Chapter 3 presents a general review of the applications of 
genomics and proteomics research in the process development research, adapted from 
[39]. This chapter discusses the application of genome-wide expression profiling tools 
in the design and optimization of bioprocesses. Chapter 4, adapted from [45], 
investigates the biological basis for the observed phenomenon that the translation rate 
of the HlyA protein may be related to the ability to secrete higher levels of HlyA via 
the Type-I pathway. A detailed comparative analysis between a hypersecreter mutant 
strain (hly-slow) and a control strain (hly-parent) has been provided.  Chapter 5 
explores the utilization of different secretion pathways in E. coli to study the effect of 
synonymous rare codon cluster on polypeptide folding and secretion. This chapter 
illustrates how the introduction of rare codons in a specific stretch of the target gene 
affects the interaction of the polypeptide with molecular chaperones and highlights the 
benefit of synonymous codon engineering in improving protein secretion via multiple 
secretion pathways for bioprocess applications. Chapter 6 discusses application of a 
‘next-generation’ genome sequencing technology for strain improvement in E. coli. 
Specifically, the study presents the discovery of a single nucleotide polymorphism in a 
derivative hypersecreter E. coli strain which can enhance the extracellular secretion of 
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recombinant proteins via the Type-I pathway. Chapter 7 summarizes the results and 
conclusions of this work and recommends areas of future work.   
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CHAPTER 2 
SECRETION PATHWAYS IN ESCHERICHIA COLI  
 
2.1 Preface  
This chapter provides an overview of the Type-I and Type-II secretory pathways that 
have evolved to translocate proteins across membranes in Escherichia coli. The 
secretory production of recombinant proteins by E. coli has several advantages over 
intracellular production. In most cases, targeting protein to the periplasmic space or to 
the culture medium facilitates downstream processing, folding, and in vivo stability, 
enabling the production of soluble and biologically active proteins at a reduced 
process cost. Systems for the export of proteins to the periplasm and those for 
secretion to the extracellular milieu are described. 
 
2.2 Introduction 
Most bacteria secrete proteins such as degradative enzymes, toxins, and other 
pathogenicity factors into the extracellular environment [1]. In Gram-negative 
bacteria, secreted proteins have to cross the two membranes of the cell envelope, 
which differ substantially in both composition and function [2]. 
 
The type I, II, III, IV, and V secretion pathways are widespread among Gram-negative 
bacteria and their mechanisms differ significantly. Despite these differences, the 
systems have, in common, a need to recognize specifically their cognate substrates and 
promote secretion without compromising the barrier function of the cell envelope [3]. 
This chapter discusses the Type-I secretion pathway for extracellular secretion and the 
Sec, SRP and Tat mechanisms for periplasmic secretion, which are used most 
commonly for recombinant protein secretion in E. coli. A brief discussion about Type-
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II extracellular secretion is also provided, which involves a two step process. The type 
III secretion pathway is characteristic of several pathogenic Gram-negative bacteria 
and has been reviewed [4]. Type IV secretion comprises those pathways usually found 
in bacterial conjugation systems [5] and has been reviewed [6]. The type V 
mechanism includes the autotransporter and the two-partner secretion systems [5], and 
has been reviewed [7]. 
 
Bacteria often sequester highly expressed expressed recombinant protein in inclusion 
bodies, which are aggregates of precipitated protein. These inclusion bodies can be 
isolated and the protein can be refolded, but this recovery often requires additional 
steps in downstream processing that can be costly. Often, purification of proteins of 
interest requires cell disruption, increasing the number of contaminant species that 
must be removed and exposing the desired product to more proteases [8].  Secretion of 
recombinant proteins to the culture medium or periplasm of E. coli has several 
advantages over intracellular production. These advantages include simplified 
downstream processing, enhanced biological activity, higher product stability and 
solubility, and N-terminal authenticity of the expressed peptide. The periplasm of E. 
coli is an oxidizing environment, which aids in the formation of disulfide bonds [8].  It 
also contains fewer protein species and proteases, reducing the complexity of the 
initial mixture of contaminants.  However, overexpression of recombinant proteins can 
also cause formation of inclusion bodies in the periplasm [9], likely due to the lack of 
ATP-dependent chaperones in this compartment.  Secretion to the extracellular 
medium is highly desirable because the concentrations of protein of interest will 
remain low, reducing the risk of aggregation.  Further, most laboratory strains of E. 
coli do not secrete any proteins to the extracellular medium [10]. Thus, problems 
associated with protease degradation are mitigated, and downstream purification of the 
 17 
secreted protein is greatly facilitated.  The extracellular medium can also be 
supplemented with cofactors or adjusted to optimal pH or osmolarity conditions to 
facilitate or to stabilize folding for the protein of interest.  Understanding and 
controlling protein translocation mechanisms can greatly facilitate recombinant 
protein production.  
 
2.3 Type I secretion 
Type I secretion systems (T1SS) are characterized by the ATP-binding cassette (ABC) 
superfamily of proteins, which are involved in many transport functions in eukaryotes 
and prokaryotes. In Gram-positive bacteria, these systems participate in drug efflux 
and in toxin and cytolysin secretion. Gram-negative bacteria also use ABC transport 
systems for uptake of iron siderophores, carbohydrates, amino acids, and oligopeptides 
[11].  ABC protein transporters are also widespread in eukaryotes, where they have 
been found to play a critical role in resistance of cancers to chemotherapy drugs and in 
the genetic mutation that causes cystic fibrosis [12]. The ABC protein transporter in 
Gram-negative bacteria translocates peptides across both the inner and outer 
membranes in a single step [13]. These transporters have evolved to transport specific 
target peptides, which include toxins, proteases, lipases, and hemoproteins [11].  
Despite their specificity, they are widespread among Gram-negative bacteria and are 
highly conserved. The α-hemolysin (HlyA) secretion pathway in pathogenic E. coli is 
the most extensively studied T1SS.    
 
A signal sequence is required for protein translocation and is conserved for particular 
families of secreted proteins. Typically, the signal sequence is located at the C-
terminus, although there is one notable exception in the export of the antibiotic peptide 
colicin V in E. coli, with a signal sequence located at the N-terminus [14]. In proteases 
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and lipases secreted by Type I systems, the C-terminus consists of several negatively 
charged amino acid residues followed by several hydrophobic ones and appears to 
form a stable α-helix [15]. Toxins, proteases, and lipases secreted by ABC 
transporters have repeating glycine and aspartic-rich (RTX) domains just upstream of 
the C-terminus signal sequence that are critical for secretion. It is hypothesized that 
these RTX regions act as internal chaperones and aid in distinguishing secretory from 
cytosolic proteins [16]. T1SS signal sequences have low sequence homology but the 
general motif is conserved in these families. Mutagenesis experiments of the sixty 
amino acid signal sequence of the toxin α-hemolysin in E. coli have shown that single 
mutations in the region do not decrease export efficiency; however, combinations of 
mutations do, implying that tertiary structure may be important in signal sequence 
recognition [17]. Signal sequences are not cleaved at any point in the translocation 
process. Hence for certain biotechnology applications (production of therapeutic 
proteins), protease sites such as thrombin can be incorporated between the reporter 
protein and the signal sequence. 
 
Gram-negative ABC protein-mediated transport systems are composed of three 
different secretion machinery proteins: the ABC protein, a membrane fusion protein 
(MFP) and an outer membrane pore protein. ABC proteins are highly conserved 
among many different species and functions. They usually consist of two inner 
transmembrane domains and two hydrophilic (cytosolic) ATP-binding domains [15].  
These cytosolic domains have ATPase activity in vitro [11] and probably provide 
energy for the translocation reaction; however, it is unknown which exportation steps 
require ATP hydrolysis, or how the energy is transferred to the secretion process.  
Studies indicate that the ABC protein is responsible for substrate specificity in the 
transport system [17]. The ATP binding-domain of HlyB, the ABC protein involved in 
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secretion of α-hemolysin has recently been crystallized [18]. It consists of a catalytic 
domain that is highly conserved among ABC transporters, and a signaling domain 
specific to each transporter. The catalytic domain is comprised of two β-sheets and 
seven α-helices and is responsible for hydrolysis of ATP. The signaling domain 
consists of five α-helices and a highly variable C-loop, which is thought to interact 
with the transmembrane domains and to recognize the transport substrate.  
Experiments have shown that ATP hydrolysis is required for translocation but not for 
assembly of the translocation complex [17].  
 
One of the membrane helper proteins is a member of the membrane fusion protein 
family (MFP), often involved in membrane transporters and antiporters. MFP genes 
are often adjacent to the genes encoding the ABC proteins [11]. Sequence predictions 
indicate that they are comprised of an N-terminal hydrophobic segment anchored in 
the inner membrane, a large hydrophilic region, probably located in the periplasm, and 
a C-terminus β-barrel structure that interacts with the outer membrane protein [15].  
The MFP is thought to permit a localized fusion of the two membranes. Recent studies 
in the Hly pathway indicate that TolC trimers in the outer membrane, surrounded by 
several HlyD monomers which also surround HlyB in the inner membrane, forming a 
continuous sealed channel from the cytoplasm to the exterior, with a molecule of 
HlyA in transit (Fig. 2.1) [19]. The actual stoichiometry of HlyD with respect to other 
components remains unclear [19]. 
 
The other membrane protein forms a pore in the outer membrane and may be general 
or specific to the translocation pathway. Biochemical evidence suggests that the outer 
membrane protein exhibits no substrate specificity [11]. In E. coli the same outer 
membrane protein TolC is used for secretion of both colicin V-1 and α-hemolysin, 
 20 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1. The Type1 translocator in E. coli. Cartoon representation of TolC trimers 
in the outer membrane, surrounded by several HlyD monomers which also surround 
HlyB in the inner membrane, forming a continuous sealed channel from the cytoplasm 
to the exterior, with a molecule of HlyA in transit. The actual stoichiometry of HlyD 
with respect to other components remains unclear. This figure is reproduced from 
[20]. 
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while the ABC and MFP proteins are specific [14]. TolC also participates in efflux of 
small noxious molecules such as detergents and anti-bacterial agents. The crystal  
structure of TolC has been solved [21], and the homotrimer appears to form an outer 
membrane β-barrel component and a large α-helical barrel segment that may interact 
with HlyD in the periplasm [21,22]. The outer membrane portion resembles that of a 
porin, forming a pore with an interior diameter of 19.8 Å [23]. The periplasmic portion 
is unique in that it appears to be self-closing when not associated with the other 
secretion machinery proteins, preventing the free diffusion of hydrophilic molecules 
into or out of the cell [24].    
 
Studies indicate that the substrate initiates the assembly of protein secretion 
machinery, and that subsequent interactions are very ordered [20]. Substrate affinity 
chromatography suggests that the substrate's C-terminus binds to the ABC protein, 
which then interacts with the MFP, which then associates with the outer membrane 
protein to effect secretion across both membranes [17]. Experiments show that the C-
terminus of HlyD interacts with the periplasmic domain of HlyB and HlyA [19], while 
the outer membrane portion of HlyD interacts with TolC to form a pore through which 
HlyA is released [24].  TolC is endogenously expressed [25] and also participates in 
the import and export process of many smaller molecules. The hly operon includes the 
hlyABD genes, as well as the gene encoding HlyC, a small post-translational activator 
of HlyA that has been shown to play no role in translocation [25]. The Hly system has 
been used to create fusion proteins with C-terminal sequences that have been 
successfully secreted in E. coli. A diverse range of heterologous proteins, such as 
antibodies, hormones, and proteases, have been secreted [25,26]; however, much 
remains unclear about other factors which may affect the secretion machinery, and the 
system's specificity for secreted substrates. Early studies attempting secretion of 
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dihydrofolate reductase (DHFR) using the Hly system did not produce an active 
enzyme; however, a single amino acid change in DHFR fused to the signal sequence 
resulted in an active enzyme that was secreted to the media. Other recombinant 
proteins were found to be secretion incompetent in an active state using the Hly 
pathway.   
 
Secretion in this pathway typically requires no chaperones [11], with the exception of 
the heme-binding metalloprotease HasA in Serratia marcescens that requires the SecB 
chaperone [26], possibly to prevent the protein from folding prior to translocation.  
The folding states of the protein at different points in the ABC transport pathway are 
as yet unclear, but folded HasA protein has been shown to be translocation-deficient, 
and may inhibit the translocation machinery by sequestering the HasABC transporter 
[27].  Experimental evidence indicates that SecB facilitates translocation of HasA by 
sequestering it in an unfolded state prior to translocation. Studies with single chain 
antibody fragments secreted using the Hly system indicate that folding and disulfide 
bonds formation occurs during the translocation process [28]. Our studies show that 
GFP can be secreted using the hemolysin pathway, but is inactive once translocated.  
As with the Sec pathway, GFP is probably maintained in an unfolded state prior to and 
during translocation, resulting in misfolded protein once outside the cell. The 
requirements for unfolded peptides prior to translocation and for unassisted folding in 
the extracellular medium limit the types of proteins that can be secreted in an active 
state using Type I secretion pathways.   
 
Many research groups are studying the Type-I secretion pathway because of its 
efficiency and widespread occurrence in both prokaryotes and eukaryotes [29]. As 
mentioned previously, ABC export mechanisms are important in cancer and cystic 
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fibrosis research; they are also of interest to the biotechnology industry, where the 
simplicity of the ABC transporter system and relatively small number of required 
machinery proteins may facilitate implementation into recombinant protein processes.  
Other researchers are investigating the use of type I pathway systems for the 
production of attenuated vaccines [30]. 
 
2.4. Sec export pathway 
The Sec system, or General Export Pathway (GEP) is responsible for export of most 
proteins in wild-type E. coli and most Gram-negative bacteria [11,31]. It utilizes 
approximately six proteins encoded by the sec gene cluster to translocate the substrate 
to the periplasm, although up to eight other helper proteins have been implicated. An 
N-terminal signal sequence [32] is recognized by chaperone proteins which prevent 
folding prior to translation; the protein is translocated into the periplasm in an 
unfolded state by the Sec system proteins [31,33]. Sec Signal sequences average 24 
amino acids in length and contain three distinct regions: a positively charged N-
terminus, a hydrophobic α-helical region, and a c-domain that contains the cleavage 
site [34]. During translation, the nascent preprotein (substrate with leader peptide 
sequence still attached) is bound by the chaperone SecB to prevent folding [33]. The 
specific interactions by which SecB identifies targets for export are unclear, as SecB 
has been shown to interact with nascent chains without a signal peptide. SecB delivers 
the preprotein to the site of translocation by binding to the membrane-bound SecA 
protein. It appears to bind directly to the signal sequence, and the preprotein is 
transferred from SecB to membrane-bound SecA. SecA can also dissociate from the 
membrane to bind to preproteins directly and transport them to the membrane [35].   
SecY and SecE are inner membrane proteins that form a core translocation complex 
and are necessary for transport [33]. SecY appears to constitute the channel by which 
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the peptide is translocated, while the exact function of SecE is unknown [35]. 
Inclusion of SecG markedly increases secretion efficiency, and SecYEG is known to 
form a complex that binds SecA at the membrane. SecA, Y, E, and G are thought to 
possess a proofreading function, rejecting defective preproteins from export [36].  
Proteins are translocated across the membrane in a stepwise fashion, powered by the 
ATPase function of SecA.  The hydrolysis of ATP produces a conformational change 
in SecA, causing it to release and rebind the preprotein, thereby threading it through 
the SecYEG translocase complex (Fig. 2.2).   
 
The membrane proteins SecD and SecF contain large periplasmic domains [31] and 
are known to complex with YajC and loosely bind to the SecYEG complex.  SecD and 
F may also be involved in release of translocated proteins by facilitating folding or 
affecting the energized state of the membrane [36], as it has been shown that their 
presence is necessary for maintaining a ∆pH.  Recent evidence also indicates that the 
SecDF/YajC complex may prevent backward sliding of the preprotein in the 
translocation channel [35].  Peptidases such as LspA and Lep in E. coli operate in the 
periplasm to cleave the leader peptides, yielding mature protein [33].   
 
Studies using reporter proteins suggest that the Sec pathway in E. coli cannot 
translocate active green fluorescent protein (GFP) from the jellyfish Aequorea victoria 
[36].  It is hypothesized that transport of unfolded GFP by the prokaryotic Sec export 
system renders the protein unable to fold correctly once released from the 
translocation channel. This observation highlights a limitation of the Sec pathway, 
namely that exported proteins must be able to fold in the chaperone-poor environment 
of the periplasm. To this end, several foldases including DsbA, which catalyzes the   
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Figure 2.2. Schematic overview of the E. coli Sec, SRP and Tat translocases. (a) Co-
translational translocation by the SRP pathway, (b) post-translational targeting routes 
and translocation of unfolded proteins by the Sec-translocase, and (c) translocation of 
folded precursor proteins by the Tat translocase. This figure is reproduced from [37]. 
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formation of disulfide bonds [31], and Skp, which aids in folding and insertion of 
outer membrane proteins [38], are found in the periplasm. Genetic modifications of E.  
coli have allowed protein export of proteins to the periplasm via the Sec pathway and 
subsequent secretion to the extracellular medium due to increased outer membrane 
permeability [39,40]. 
 
2.5 SRP Pathway 
The signal recognition particle (SRP) pathway is used by E. coli primarily for the 
targeting of inner membrane proteins [41]. This system has been exploited in the 
secretion of several recombinant proteins including Mtla–OmpA fusions [42], MalF–
LacZ fusions [43], maltose binding protein, chloramphenicol acetyl transferase 
[44,45], and haemoglobin protease [46]. 
 
SRP recognizes substrates by the presence of a hydrophobic signal sequence (hence 
the name signal recognition particle). The presence of an N-terminal signal sequence 
with a highly hydrophobic core, combined with a lack of a trigger factor binding site 
[47], results in co-translational binding of the nascent chain to Ffh [48]. For a 
productive interaction between the preprotein and Ffh, 4.5S RNA is required [49]. It 
has been suggested [50] that the interaction between SRP and the signal sequence is 
dependent on the hydrophobicity of the nascent chain since preproteins with more 
hydrophobic signal sequences are translocated with higher efficiency. It has been 
shown [51] that SRP binds the ribosome at a site that overlaps the binding site of 
trigger factor. A discriminating process has been proposed in which SRP and trigger 
factor alternate in transient binding to the ribosome until a nascent peptide emerges. 
Depending on the characteristics of the nascent peptide, the binding of either SRP or 
trigger factor is stabilized, thus determining whether the peptide is targeted to the 
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membrane via the SRP pathway, or post-translationally by the SecB pathway [51]. 
 
FtsY is found both in the cytoplasm and at the membrane [49], and can interact with 
ribosomal nascent chain–SRP complexes in the cytosol (Fig. 2.2). Upon interaction 
with membrane lipids, the GTPase activities of FtsY and Ffh are stimulated, thus 
releasing the nascent chain to the translocation site [52]. This site may be the SecYEG 
translocon [53], although it has been demonstrated that membrane insertion can occur 
independently of SecYEG [54]. Insertion of transmembrane segments can occur in the 
absence of SecA [55] while translocation of large periplasmic loops is SecA-
dependent [56].  
 
For recombinant protein production, SRP targeting can be achieved by engineering the 
hydrophobicity of the signal sequence [57]. This is advantageous if the target protein 
folds too quickly in the cytoplasm, adopting a conformation incompatible with 
secretion by the SecB-dependent system [58]. 
 
2.6 Tat Pathway 
The TAT pathway is capable of transporting folded proteins across the inner 
membrane [59] independently of ATP [60] using the transmembrane PMF [61]. In 
most cases, the substrates of this pathway are proteins that bind specific cofactors in 
the cytoplasm and are folded prior to export [62,63]. This system is related to the 
DpH-dependent protein import machinery of the plant chloroplast thylakoid 
membrane [64]. The TAT pathway has been used in the secretion of several 
recombinant proteins including antibody fragments [65], green fluorescent protein 
[66,67] and several others.  
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The main components of this translocation system in E. coli are TatA, TatB and TatC 
proteins. TatA has been proposed to form the transport channel [68], although TatAB 
complexes have also been implicated in that function [69]. TatB and TatC are 
proposed to form a 1:1 complex that may provide the initial binding site for preprotein 
docking [70-72]. It has also been proposed that the signal sequence is recognized by 
TatC and then transferred to TatB [73]. A mechanism for protein translocation by the 
TAT system was recently proposed [74]. In this study, the authors propose that the 
signal peptide is recognized by TatC, which is forming a complex with TatB. When 
signal peptide binding occurs, proton motive force promotes the association between 
the TatBC complex and TatA oligomers. The folded preprotein is then translocated by 
the TatA channel and the leader peptide is processed (Fig. 2.2). Following 
translocation, TatA dissociates from the TatBC complex [74]. It has also been reported 
that TatE can partially substitute TatA [75]. 
 
Like Sec signal peptides, TAT signal peptides are also composed of three regions: a 
positively charged region (n-region), a hydrophobic region (h-region), and a c-region 
that contains the cleavage site [76]. The average size of these signal peptides is 
approximately 38 amino acids, which is 14 amino acids longer than the average Sec 
leader peptide. Most of this additional length is due to an extended n-region. TAT 
signal peptides bear the N-terminal consensus motif S/T-R-R-X-F-L-K, where X is 
highly variable [76]. Although the presence of both arginine residues is not an 
obligatory requirement for transport, mutagenesis of one or both of these residues can 
affect membrane translocation [66,77]. The h-region of TAT signal peptides is usually 
less hydrophobic than that of Sec leader peptides. The c-region contains the cleavage 
site and shows a strong bias towards basic amino acid residues [75]. It has not been 
established whether these signal peptides are cleaved by signal peptidase I or by some 
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other protease [78].  
 
Tat systems translocate folded proteins across biological membranes [79] and 
therefore it is believed that its physiological role is to extend the set of translocatable 
substrates to those that fold prior to translocation. This is the fundamental functional 
difference to the Sec system, which only translocates largely unfolded proteins [80]. It 
has been proposed that the Tat system is used only in cases where cytoplasmic folding 
excludes the use of the Sec system [81]. Tat substrates fold inside the cytoplasm and 
thus can use general chaperones for folding. Specific chaperones have been implicated 
in preventing translocase interactions prior to cofactor insertion and folding, leading in 
many cases to an oligomerization of the substrate protein [82]. This has been termed 
“proofreading” and used to describe a function that prevents targeting prior to folding 
[83]. Although general chaperones likely suffice to ensure folding of Tat substrates, an 
additional folding quality control at the Tat system may exist to ensure that only 
folded proteins can pass the translocase [84]. This selectivity at the Tat translocase can 
be observed with overexpressed folding-impaired artificial Tat substrates [84], but so 
far no evidence for a biological requirement of this quality control system at the Tat 
translocase has been demonstrated.  
 
2.7 Type II secretion 
The general secretory pathway is a two-step process for the extracellular secretion of 
proteins mediated by periplasmic translocation [3]. Three pathways can be used for 
secretion across the bacterial cytoplasmic membrane: the SecB-dependent pathway, 
the signal recognition particle (SRP), and the twin-arginine translocation (TAT) 
pathways. The second step (translocation across the outer membrane) involves specific 
protein machinery. Extracellular secretion by a type II mechanism constitutes the main 
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terminal branch (MTB) of the general secretory pathway. This step is complex and 
requires 12–16 proteins that constitute the secreton [85-88]. Although the functions of 
individual secreton components are not known, some roles have been attributed by 
comparative analysis with other secretons that are highly conserved among Gram-
negative bacteria [87-89]. When exiting peptides reach the periplasm, they are thought 
to adopt tertiary and even quaternary structures in order to be recognised by the MTB 
components. Although it is known that proteins have to adopt secretion-competent 
conformations to proceed further [85-86], no secretion signal on the folded proteins 
has been identified [87]. 
 
2.8 Conclusion 
Bacteria have evolved a diversity of mechanisms to transport proteins to the periplasm 
(via the Sec, SRP and Tat pathways), to the extracellular medium (via the Type-I and 
Type-II pathways), or directly into a target cell (via the Type-III and Type-IV 
pathways). The knowledge about the functional role of individual components in the 
secretion pathways can help us to understand disease progression related to various 
bacterial infections and may enable better understanding of secretion of therapeutic or 
vaccinating agents in gene therapy. Protein secretion in bacteria is also of great 
interest for applications in recombinant DNA technology and the advances in our 
understanding of specific pathway mechanisms can provide new tools and 
technologies to improve recombinant protein expression for the production of 
therapeutically relevant proteins.  
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CHAPTER 3 
GENOMICS AND PROTEOMICS IN PROCESS DEVELOPMENT: 
OPPORTUNITIES AND CHALLENGES 
 
3.1 Preface  
There have been increasing efforts to apply genome-wide expression profiling tools to 
understand cell culture process development with the goal of strain improvement or 
process improvement. This chapter is adapted from: Gupta, P., and Lee, K.H. 2007. 
Genomics and Proteomics in Process Development: Opportunities and Challenges. 
Trends in Biotechnology 25: 324-330 and presents a review of the application of 
genomics and proteomics in process development.  
 
3.2 Abstract 
Global gene expression profiling by genomic and proteomic analyses has changed the 
face of drug discovery and biological research in the past few years. The impact of 
these technologies in the area of process development for recombinant protein 
production has been increasingly realized. This review discusses the application of 
genome-wide expression profiling tools in the design and optimization of bioprocesses 
with an emphasis on the impact on process development of mammalian cell culture. 
Despite a lack of genome sequence information for most relevant mammalian cell 
lines used, these technologies can be applied during various process development 
steps. Although, there are only a few examples in the literature that present a 
significant improvement in productivity based on genomics and proteomics, further 
advances in analytical tools and genome sequencing technologies will greatly increase 
our knowledge at the molecular level and will drive the design of future bioprocesses. 
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3.3 Introduction 
The market for biopharmaceuticals is estimated to increase from USD$33 billion to 
more than USD$70 billion by the end of the decade [1]. Overall, some 165 
biopharmaceutical products (recombinant proteins, monoclonal antibodies and 
nucleic-acid based drugs) have Food and Drug Administration (FDA) approval and 
several thousand are in discovery and pre-clinical development [1]. As a result there is 
a need for efficient, cost-effective systems for the production of these molecules.  
 
Most biopharmaceuticals are produced through the use of recombinant DNA 
technology, wherein a recombinant ’production system’ is created based on a 
genetically modified host cell. These production systems usually involve either 
microbial fermentation or mammalian cell culture among other platform technologies. 
In addition to fermentation, the extraction and subsequent purification of desired 
proteins from the fermentation broth is an important part of the overall production 
process of biopharmaceuticals. These downstream procedures form an integral part of 
the overall process development (Fig. 3.1) and are crucial in determining the final 
productivity and characteristics of the product. It is essential that a suitable production 
process is designed before pre-clinical trials and that the process is scalable and yields 
a sufficient amount of therapeutic protein. Hence, extensive early development work is 
essential. Traditionally, process development involves designing and optimizing 
upstream and downstream processes based on empirical data, with only incomplete or 
limited understanding at the cellular level. The advent of genomic and proteomic 
technologies, which can provide molecular level details, has generated interest in the                               
application of these tools to process development. This review discusses the role of 
these approaches in the context of improving different stages of process development, 
including both upstream and downstream processes. The applications to mammalian 
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cell culture are emphasized because production processes for these cells are more 
complex than for microbial culture and because there is a growing importance on the 
use of mammalian cells as a production platform. 
 
3.4 Role of Genomics and Proteomics 
Genomics is the comprehensive analysis of the genetic content of an organism and 
also often refers to genome-wide studies of mRNA expression [2] Proteomics is the 
study of the expressed protein complement of a genome at a specific time [3]. The 
drivers of genomic and proteomic analyses are the technological achievements of the 
past decade that enable a reasonably quantitative analysis of DNA sequence, mRNA, 
and protein expression inside cells and include tools such as DNA microarrays, two-
dimensional gel electrophoresis (2DE), and mass spectrometry (MS). The application 
of these methods in drug discovery has heralded a new era for target identification and 
these efforts have been reviewed recently [4-7]. These genome-wide approaches have 
been adopted by biotechnology and pharmaceutical industries to complement 
traditional approaches to target identification and validation, for hypotheses 
generation, and for experimental analyses in traditional-based methods.  
 
An equally important, but less-often discussed, issue is the impact of genomics and 
proteomics on process development (Fig. 3.2). From the process development 
perspective, these tools might significantly aid in at least three areas: 1) exploration of 
cellular functions to enhance productivity or influence desired properties of biological 
products (upstream), 2) learn and apply knowledge of cell function in response to 
environmental change, including exposure to normal and unusual substrates, and 3) 
exploit knowledge of cell function and properties to improve product purification and 
characterization (downstream). 
 
 42 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2. A possible role of genomic and proteomic tools in process development. 
Fundamental understanding of genomic and proteomic processes can facilitate the 
selection of productive organisms. It can also facilitate product/impurity 
characterization between different cell lines, leading to better integration of upstream 
and downstream processing operations. In theory, further improvements may be made 
using genomic and proteomic analyses, in an iterative fashion. These resulting systems 
can then be used by late stage process development to validate and scale up the 
process. 
 
 
Genomics 
& 
Proteomics
Stable 
Genotype &
Enhanced
Phenotype
Product 
Characterization
Predictive
Design of 
Integrated
Bioprocess
Enhanced 
Selective 
Recovery
Optimized 
Expression 
systems  
Optimized 
Process 
Early Stage 
Process Development
Late Stage
Process Development
 43 
3.5 Mammalian Cell Culture 
The advances made in mammalian cell culture technology during the past two decades 
have been greatly facilitated by genetic and physiological manipulation of cells. 
Today, approximately 60-70% of all recombinant protein pharmaceuticals are 
produced in mammalian cells [8]. The major mammalian cell lines that have gained 
regulatory approval for recombinant protein production are Chinese hamster ovary 
(CHO), mouse myeloma (NSO), baby hamster kidney (BHK), human embryo kidney 
(HEK-293) and human retinal cells [8]. Of these, CHO is the most widely used cell 
line. However, the genetic and physiological properties that enable CHO cells to be 
capable producers are not fully understood. Although whole genome microarrays are 
commercially available for mouse and human cell lines, there is a lack of genome 
sequence information available for CHO [9]. Progress has been made in the large-
scale expressed sequence tag (EST) sequencing of cultured mammalian cell lines 
designed specifically for recombinant protein production [10]. In that effort, two 
cDNA libraries were constructed from three CHO cell lines grown under different 
media conditions. These libraries led to the construction of a cDNA microarray 
containing 4608 ESTs, which yielded 2602 unique assemblies upon sequencing, of 
which 76% were annotated as orthologs of sequences in the GenBank database 
(http://www.ncbi.nlm.nih.gov/Genbank). This initiative also revealed that CHO 
sequences are generally most similar to those of the mouse. It is very likely that with 
advances in sequencing technologies, we will see more refined and accurate cDNA 
microarrays for this important cell line in the near future. 
 
3.5.1 Upstream Process Development  
Cell Culture Media 
A significant challenge in process development is to establish well-defined 
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manufacturing processes that are robust and reproducible. One of the most important 
factors that can affect a cell culture process is the culture media. Fetal Bovine Serum 
(FBS) has been the most widely used growth supplements for cell cultures, primarily 
because of its high levels of growth stimulatory factors. However, the quality, type, 
and concentration of the components in different FBS lots can affect the cellular 
growth rate in a fermentation process [11]. In a recent study, the growth rates of adult 
retinal pigment epithelial cells (ARPE-19) were evaluated using three different lots of 
FBS [12]. The authors used proteomic techniques, based on reverse-phase liquid 
chromatography (LC) coupled with ion-trap tandem MS analysis, to examine the 
variability of important growth stimulatory and inhibitory proteins in different FBS 
serum lots. The study revealed that serum lots resulting in the highest growth rates 
contained additional growth factors and related proteins that were not found in the 
other two serum lots. 
 
Currently, a major focus in cell culture media development is the formulation of 
serum-free and animal-product-free media that can result in consistent growth and 
productivity without disease transmission. High-throughput genomic and proteomic 
tools can have a vital role in medium development and optimization. A recent study, 
using microarray analysis, identified specific receptors, cell adhesion molecules, and 
cell-signaling factors expressed during cell growth [13]. This information led to the 
identification of corresponding ligands and small molecules that might be incorporated 
into media to test for the desired effect on given cellular processes. Another recent 
study involving the development of protein-free media suggested that zinc metal could 
be used as an insulin replacement in murine hybridoma cultures [14]. In this transcript 
analysis, using mouse oligonucleotide array and quantitative real time reverse 
transcriptase polymerase chain reaction (RT-PCR), indicated no major change in the 
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global expression profile between the insulin and zinc supplemented cultures, which is 
consistent with their similar growth and metabolic characteristics and monoclonal 
antibody production profiles. 
 
Cell line selection and engineering 
The ability to produce and select for a high producing cell line is key to the initial 
stages of bioprocess development. In the case of mammalian cells, the recombinant 
gene with the necessary transcription regulatory elements is transferred to cells along 
with a second gene that confers a selective advantage to the recipient cells. Most 
commonly, dihydrofolate reductase and glutamine synthetase genes are used for 
selection in CHO cells. To improve recombinant protein production from mammalian 
cells, various molecular strategies have been used at the level of gene copy number, 
transcription, translation, posttranslational modification and secretion, as reviewed by 
[8]. Despite these studies, the bottlenecks in the cellular machinery for efficient 
recombinant protein production are still unclear.  
 
The site of incorporation of the recombinant genes within the genome of the host 
mammalian cell is crucial in determining gene stability and productivity [15-16]. 
Techniques for the introduction of recombinant genes into mammalian cells is a 
random process and results in a clone-to-clone variation in protein productivity for a 
given cell line, resulting in a wide range (may exceed two orders of magnitude) of 
protein expression levels of different cell clones [17-18]. Recently, a study analyzed 
how GS-NS0 mammalian cell transfection produces variant cell lines with distinct 
characteristics in terms of productivity of monoclonal antibody anti-CD38 [19]. The 
authors used genomic quantitation approaches, Northern and Southern analysis, to 
define molecular rationales for high and low level producers and to describe processes 
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that allow cells to escape the stringency of selection procedures. It was found that 
>50% of the transfectants studied had molecular defects at the level of cDNA and/or 
mRNA, including defects in the regulatory regions. A similar study explored the 
regulation of recombinant monoclonal humanized IgG production in CHO cells by a 
comparative study of gene copy number, mRNA level, and protein expression between 
two different cell families, each containing one parental cell line and two progeny cell 
lines (amplified in the presence of methotrexate) [20]. The authors observed that 
progeny cell lines in both families had higher productivities than parental cell lines 
and concluded that it might be as a result of gene amplification and enhanced 
transcriptional efficiency.  
 
A proteomics study of whole cell extracts from four stably transfected GS-NS0 cell 
lines that differ in recombinant monoclonal antibody IgG4 productivity (qMAb) used 
2DE coupled with MS [21]. A significant increase in abundance of proteins including 
molecular chaperone (BiP), endoplasmin, and protein disulphide isomerase was 
measured with increasing monoclonal antibody (MAb) productivities. In another 
study, the functional categorization of 76 proteins, which were differentially expressed 
among the same four GS-NS0 cell lines, was also presented [22]. The authors revealed 
that protein synthesis, degradation, and nucleic acid synthesis and processing protein 
categories did not change in abundance. However, ER chaperones, non ER-
chaperones, and cytoskeletal protein categories all increased significantly with 
elevated qMAb, inferring that the rate of production of MAb in GS0 cells is limited by 
the availability of processing and/or secretory apparatus of the cell.  
 
Genomic and proteomic approaches can also offer new insights into cellular 
metabolism and physiology for metabolic engineering. This type of combined 
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approach has been used to understand the molecular mechanism of metabolic shift in 
the mouse hybridoma cell line (MAK) [23]. Metabolic shift is a consequence of 
controlled nutrient feeding to maintain low concentrations of glucose and glutamine, 
which results in higher cell concentration in continuous cultures. In this study, two cell 
lines with different ratios of glucose consumption to lactate production were studied 
using mouse cDNA microarrays to identify differentially expressed mRNA transcripts 
and 2DE-MS to identify differentially expressed proteins. It was suggested that 
metabolic shift is a combined effect of both biochemical events at the metabolic 
reaction level and gene expression at the transcription and translation levels. This 
approach of integrating transcriptional profiling, proteomic techniques and 
biochemical analysis constitutes what has been termed as systems biology [24-25] and 
can provide a comprehensive understanding of mammalian cells in culture.  
 
Recently, large-scale gene expression analysis was performed to better understand the 
cholesterol-dependent phenotype of NS0 myeloma cells [26]. Transcriptional analysis 
between a cholesterol-dependent cell line and a cholesterol-independent cell line was 
performed using mouse Affymetrix GeneChipsTM. Proteomic analysis was performed 
using 2DE coupled with MS. Most of the genes involved in cholesterol biosynthesis, 
lipid metabolism, and central energy metabolism were expressed at lower levels in 
cholesterol-independent cell line, indicating that the reversal of cholesterol 
dependency has a profound effect on cell physiology.  
 
2DE has also been used to analyze the simultaneous expression of several important 
cell cycle regulatory proteins [27]. This study found that cyclin D1, cyclin E, and E2F-
1 proteins appear to have the strongest correlation to the mitogenic strength of growth 
stimulation of CHO cells. The authors hypothesized that the deregulated expression of 
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these proteins might bypass the requirement for external growth factor signaling. 
Transfection with a vector encoding cloned cyclin E and overexpression of cloned 
E2F-1 have independently been shown to activate proliferation of CHO cells in the 
absence of serum and external growth factors [28-29]. The new insights gained from 
all of these studies will continue to facilitate the development of advanced host strains, 
new processes, and new strategies of process development. 
 
Cell Culture Conditions 
Temperature 
One area in which there is significant interest is the use of reduced temperature 
cultivation for enhanced protein production in mammalian cells. The effect of culture 
temperature on CHO cell growth and recombinant protein productivity has been 
investigated extensively [30-34]. These studies revealed that low culture temperature, 
in a range of 28-34ºC, improves protein productivity, even though specific growth rate 
is decreased. To exploit these responses fully, the molecular responses governing 
cellular adaptation to cold-shock in mammalian cells needs to be better understood. 
 
Kaufmann and co-workers used 2DE to show that CHO cells respond to low culture 
temperature (30ºC) by synthesizing specific cold-inducible proteins, which might 
arrest cell proliferation in the G1 phase of the cell cycle [35]. Recently, transcriptome 
and proteome analyses of low temperature-induced expression in CHO cells, 
producing erythropoietin, were performed [36]. Proteomic analysis identified nine 
proteins, including some chaperones, with differential expression under conditions of 
low-temperature (33ºC). Genomic analysis using rat and mouse cDNA arrays revealed 
differential gene expression of various cellular processes including metabolism, 
transport, signaling etc. However, of the nine proteins identified by proteomic 
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analysis, the mRNA transcript expression patterns of only four proteins were detected 
in rat arrays. Similarly only two proteins were detected in the mouse arrays.  
 
Hyperosmotic Pressure 
Genomics and proteomics can also be used to help understand intracellular and 
physiological changes in cells and to obtain better insight into possible environmental 
or genetic manipulations for increasing productivity. Environmental manipulation of 
hyperosmotic pressure, which can be induced by adding salts or sugars to culture 
media, is one strategy thought to be highly feasible for improving desired protein 
productivity in recombinant CHO cell culture [37-38]. However, because cell growth 
is compensated at elevated osmolarity, the specific protein productivity does not 
increase substantially. To better understand the intracellular response of CHO cells to 
hyperosmotic pressure, proteomics of CHO cells producing a chimeric antibody under 
hyperosmotic pressure was performed [39]. Interestingly, under hyperosmotic 
conditions in which sodium chloride was added to a final osmolality of 450 mOsm/kg-
media, the authors found an increase in protein expression of pyruvate kinase and 
glyceraldehydes-3-phosphate dehydrogenase and decrease in tubulin expression. 
Separately, a genome-wide analysis of the transcriptional response of the murine 
hybridoma cell line, OKT3, towards hyperosmotic stress using DNA microarrays was 
investigated [40]. The authors obtained a list of 215 genes that were differentially 
expressed in response to osmotic shock, including genes related to immunoglobins, 
metabolism/catabolism, cell cycle regulation, signaling pathways, etc.  
 
Small chemical compounds  
The effect of small chemical molecules on recombinant protein productivity and 
quality is also an important area of research and has benefited from genomic and 
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proteomics approaches. Cytochalasin D, a fungal metabolite, enhanced protein 
productivity in CHO cells. In a study of CHO cells, a proteomic comparison was made 
between a productive recombinant clone selected at high methotrexate (MTX) 
concentration and clones of intermediate and low productivities [41]. The authors used 
this data and noted a fourfold increase in actin-capping protein (CapZ). Because the 
function of CapZ is similar to the effects of a small molecule cytochalasin D, the 
authors hypothesized that the addition of cytochalasin D might result in enhanced 
productivity and product secretion. In combination with MTX gene amplification, the 
addition of cytochalasin D resulted in a 52- to 150-fold increase in recombinant 
protein productivity.  
 
A proteomics approach was used to investigate the effects of butyrate and zinc 
sulphate on the overall proteome of a recombinant CHO cell line producing human 
growth hormone were investigated using a proteomics approach [42]. This study 
found that the addition of these compounds induced metabolic and stress protection 
proteins. Another recent study evaluated the effect of elevated ammonium ion 
concentration (media supplemented with 10mM ammonium choloride) on 12 
glycosylation related genes in CHO cells, producing constitutively expressed tissue 
plasminogen activator (t-PA) [43]. The authors, using quantitative real time RT-PCR, 
observed decreased gene expression for cytosine monophosphate-sialic acid 
transporter, β(1,4)-galactosyltransferase, uridine diphosphate-glucose 
pyrophosphorylase and α(2,3)-sialyltransferase proteins for the ammonium treated 
culture. The study concluded that lower levels of these key glycosylation enzymes and 
transporters cause a higher molecular heterogeneity of t-PA glycoforms under 
ammonium stress. 
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3.5.2 Downstream Process Development 
The application of –omics technologies in protein purification and characterization has 
been an active area of interest. However, as compared to the cell culture end of the 
process, the impact of these technologies on the downstream end of the process 
development has not been fully realized. The lack of significant studies, impacting this 
important process, might be a result of the biochemical nature (versus cellular nature) 
of these processes. 
 
The paradigm of routine biomanufacturing is to ensure batch-to-batch consistency in 
product purity, efficacy, and safety. Alterations to structural features such as protein 
fold or post-translational modification (glycosylation, phosphorylation, etc.) can alter 
product efficacy. It is thus important to identify and monitor these critical parameters 
during production to assess the effect of changes in cell culture conditions on product 
quality. In particular, the number of oligosaccharide structures associated with specific 
fermentation can be highly variable [44-45]. Traditionally, protein gel electrophoresis 
has been used to assess purity and integrity of the secreted product isolated from the 
culture supernatant [46]; LC and MS have been used to identify the protein product 
and to study its structure and glycosylation [47-48]. An important advancement in the 
characterization of glycosylation is the use of capillary electrophoresis-MS. This 
technique was used recently to accurately determine 44 glycoforms of recombinant 
human erythropoietin with high mass accuracy (± 1 Dalton) [49]. Despite the precision 
of these technologies, all of these approaches depend on extensive purification 
protocols, which might be time consuming and expensive.  
 
Recently, a proteomic technique was used to characterize overexpressed recombinant 
t-PA from a CHO cell culture lysate [50]. The authors used reversed phase capillary 
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LC-linear ion trap/Fourier transform MS to identify and characterize all the major 
glycoforms of t-PA [51], with 92.2% sequence coverage. This technology can be 
helpful in monitoring the glycosylation patterns during the fermentation process, 
thereby alleviating the need of purification for product characterization. Industrially, 
this strategy can be very useful in the development of process analytical technology 
applications, in which glycosylation can be a key indicator of cell viability as well as 
product quality.  
 
The removal of CHO-derived proteins from the biopharmaceutical product is often 
monitored using multi-product immunoassays [52-53]. To address whether underlying 
differences between CHO cell lines result in sufficient protein expression changes, a 
comparative proteomics study of three independently generated CHO cell lines was 
performed [54]. This study yielded only 11 qualitative changes and 26 quantitative 
changes greater than two-fold in protein expression out of a total of 1000 statistically 
analyzed proteins. Identification of these protein spots by MS revealed that many of 
the observed changes were due to post-translational modifications. These results 
support the idea of using multi-product immunoassays to monitor host cell protein 
impurities in different CHO cell lines.  
 
3.6 Microbial Cell Culture 
As could be expected, the literature related to industrially relevant microorganisms is 
greater than that for mammalian cells lines. We will refer the reader to several 
excellent papers and reviews, which illustrate the effect of –omics technologies in the 
process development of microbial cell culture. Genome sequencing and annotation of 
many industrially relevant microorganisms forms the foundation for relatively simple 
strain and process development. Expression profiling such microorganisms generates 
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valuable information that can be used for the development of metabolic and cellular 
engineering strategies to enhance the yield and productivity of recombinant proteins 
and to modify cellular properties to impact process development, as reviewed 
previously [55-57]. 
 
There have been several reports on proteome profiling [58-66] and transcriptome 
profiling [67-72] of Escherichia coli strains producing recombinant proteins. Apart 
from investigating the effects of culture conditions (media substrates, temperature, pH 
etc.), many of these studies present a metabolic rationale to increase the recombinant 
protein production, often by co-expression of one or more proteins of specified 
activity along with the protein of interest. Of particular interest is a transcriptomic and 
proteomic analysis of global physiological changes in E. coli during high cell density 
cultivation (HCDC) [73]. In this study, DNA microarray and 2DE analyses revealed 
that the expression of amino acid biosynthesis genes was decreased as cell density 
increases, which might be the cause for reduced productivity of recombinant proteins 
during HCDC. However, the expression of chaperones was increased during HCDC, 
suggesting that the high-density condition can be stressful to the cells. This type of 
global analysis can provide invaluable information in developing metabolic 
engineering and fermentation strategies in industrially relevant HCDC. 
 
3.7 Future Perspectives 
New proteomics and genomics technologies such as shotgun proteomics and other 
quantitative methods have been used extensively in drug discovery and understanding 
the complex cellular processes, as reviewed in [74-75]. Although, these emerging 
methods have not yet been applied comprehensively in the process development 
because they are relatively new, these technologies have the potential to increase the 
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impact of genomics and proteomics on the design of future bioprocesses.   
 
3.8 Conclusion 
Advances in genomic and proteomic technologies are transforming the drug 
development process. While there are challenges associated with the collection and 
analysis of large datasets generated by such technological applications, a topic not 
discussed in this review, genome-wide analysis of expression profiles can be greatly 
beneficial in understanding living systems. These beneficial effects on the industry are 
more clear at the discovery level because of the relatively larger investment made at 
that level. However, the impact on process development and manufacturing should not 
be underestimated. There are increasing efforts to apply these technologies to 
understanding cell culture process development with the goal of strain improvement or 
process improvement. Unfortunately, a significant number of these efforts result only 
in "lists of proteins" that change significantly and fall short of demonstrating the 
impact of the controlled expression of those genes or proteins on desired phenotypes. 
Thus, although there is considerable work being done in using these methods and there 
is great promise in the application of these methods, there is at this time, relatively few 
examples that demonstrate the significant impact of genomics and proteomics on 
process development. 
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CHAPTER 4 
SILENT MUTATIONS RESULTS IN HLYA HYPERSECRETION BY 
REDUCING INTRACELLULAR HLYA PROTEIN AGGREGATES 
 
 
4.1 Preface  
This chapter is adapted from: Gupta, P., and Lee, K.H. 2008. Silent mutations result in 
HlyA hypersecretion by reducing intracellular HlyA protein aggregates. Biotechnology 
and Bioengineering 101: 967-974. It describes the differences between the parent and 
a hypersecreter E. coli strain, containing a synonymous rare codon cluster in the gene 
of interest. The results suggest that production of high levels of secreted proteins 
requires a balance between translation and secretion rate. 
 
4.2 Abstract 
Escherichia coli is one of the most widely used hosts for the production of 
recombinant proteins. Extracellular protein secretion has the advantage of reducing 
protein aggregation and simplifying downstream purification. The introduction of five 
rare codons in a specific region of α-hemolysin (hlyA) gene previously was shown to 
result in eight-fold improvement in secretion of HlyA via the hemolysin (Type-I) 
pathway. Here we investigate the biological basis for the observed phenomenon that 
the translation rate of HlyA protein may be related to the ability to secrete higher 
levels of HlyA via the Type-I pathway. A detailed comparative analysis between a 
hypersecreter mutant strain (hly-slow) and a control strain (hly-parent) shows a 
significant decrease (by ~ 50%) in the intracellular level of HlyA protein in the hly-
slow strain relative to the hly-parent strain. Nearly 100 % of the intracellular HlyA 
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protein exists in the inclusion body fraction in both the strains. These results 
demonstrate the importance of synonymous codon changes in the context of 
improving HlyA secretion yield via Type-I pathway and further illustrate that 
production of high levels of secreted proteins appears to require a balance between 
translation and secretion rate. 
 
4.3 Introduction 
The annual global market for biopharmaceuticals is estimated at more than $30 billion 
and products derived from Escherichia coli  represent nearly 39% of all the 
biopharmaceuticals made in the US and EU [1]. Intracellular expression of proteins in 
the cytoplasm often results in the formation of inclusion bodies, which are not 
functional and difficult to process, thereby increasing production cost and reducing 
yield [2]. Secretion of heterologous protein in the periplasm can simplify purification 
processes but high levels of transport are difficult to sustain and the export 
mechanisms are not well understood. Inclusion bodies may also form in the periplasm 
as a consequence of over-expression of recombinant proteins [3].   
 
From a biotechnology perspective, heterologous protein secretion into the extracellular 
medium is desirable because the concentration of the protein of interest remains low, 
thus minimizing protein aggregation. Additionally, the extracellular environment can 
be controlled to provide optimal osmolarity and pH for protein folding and stability. 
However there have been relatively few successful attempts to secrete proteins into the 
extracellular medium, some of which have been reported [4-8]. Efforts to alleviate 
bottlenecks in secretion pathways via metabolic engineering do not often produce the 
desired phenotype, primarily because of the low efficiency and high specificity of 
most secretion systems and an incomplete understanding of their mechanisms. While 
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E. coli exports several types of proteins to the periplasm, secretion pathways to the 
extracellular medium are often specific for only a few proteins. Understanding and 
controlling translocation mechanisms enables better control over the secretion systems 
for the production of recombinant proteins. 
 
The Type-I secretion or hemolysin pathway is one of the simplest secretion systems 
and has the ability to secrete recombinant proteins directly past the outer membrane. It 
is responsible for the translocation of a 107 kDa α-hemolysin protein (HlyA) directly 
from the cytoplasm of pathogenic E. coli strains to the extracellular medium [9]. The 
Type-I secretion machinery is composed of three membrane-associated proteins: 
HlyB, HlyD, and TolC [10]. The use of the hemolysin pathway to secrete some 
recombinant proteins has been shown to produce efficiencies of up to 3-5% of total 
cellular protein accumulating in the medium, which corresponds to approximately 2.3 
mg/L/OD [4].  
 
Previous studies have established that the protein synthesis rate is an important 
consideration for secretion efficiency [6,11]. Of the number of factors that can affect 
protein synthesis rate, the effect of plasmid copy number, translation initiation region, 
and differences in codon usage on protein secretion have been studied in greater detail. 
Recent studies have shown that E. coli transformed with plasmids with different copy 
numbers exhibited altered export of human proinsulin to the periplasm [12]. In this 
study, it was found that the use of plasmids of moderate copy number (15-60) versus 
low copy number (11) increased export by two-fold, but the study did not include a 
high copy number plasmid. Studies on the export of recombinant proteins to the 
periplasm [11] revealed that a change in the sequence of the translation initiation 
region (TIR) affects the rate of translocation by the Sec pathway. However, an 
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increase in protein expression levels (brought about by differences in the strength of 
TIR) did not uniformly increase the amount of protein secreted. Rather, the optimal 
TIR (and presumably, expression level) varied for each protein tested. The 
investigators speculated that the change to the first few codons in the gene sequence 
that were made might affect the structure of the mRNA resulting in enhanced binding 
and translation by the smaller ribosomal subunit. Nevertheless, this study 
demonstrated that an optimum translational level exists to achieve high-level secretion 
of each heterologous protein, and outside of this optimum level, secretion levels drop 
off precipitously.  
 
We previously reported that synonymous codon changes (specifically changing 
abundant codons to rare codons) in a specific region of hlyA gene resulted in an eight-
fold improvement in active HlyA secretion relative to the parent strain [6]. The 
improved HlyA secretion rate was quantified by liquid blood lysis assay [6]. Rare 
codons are defined as those codons whose corresponding tRNA concentration is less 
than 1% of the total tRNA concentration [as tabulated in [13]]. The resulting strain, 
hly-slow, contained five synonymous codon changes in the hlyA gene and was 
engineered to have a predicted 37% decrease in HlyA translation rate [14]. The study 
suggested that an optimal translation rate is required for maximum secretion of HlyA 
protein via Type-I secretion pathway. Here, we perform a comparative analysis of the 
hly-parent and hly-slow strains to better understand the enhanced secretion phenotype 
in the hly-slow strain. Specifically, we show that the presence of rare codons in the 
hly-slow strain results in less HlyA aggregates relative to the hly-parent strain and 
consequently more active secreted HlyA in the hly-slow strain.  
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4.4 Materials and Methods 
4.4.1 Plasmids and strains 
All plasmids used in this study are shown in Table 4.1. Plasmids pWAM1097 and 
pWAM716 [15,16] were obtained from Rodney Welch (University of Wisconsin-
Madison). The strains used in this study are W3110-based and are listed in Table IB. 
6X-His tagged hlyA gene was constructed as follows. First the hlyA gene from 
pWAM1097 was PCR amplified with specific forward primer 5’- 
CAGTGCTAGCACATCATC ACCATCACCATATGCCAACAATAACC GC- 3’ 
containing 6X-His tag and NheI restriction enzyme site and reverse primer 5’- 
GCAGAAGCTTTTATGCTGATGCTGTCAAAG - 3’ incorporating HindIII 
restriction enzyme site. Second, this PCR product was double digested with NheI and 
HindIII restriction enzymes and ligated into the same sites of pWAM1097 vector to 
form pWAM1097_HisHlyA plasmid. phlyslow plasmid was created by site directed 
mutagenesis of pWAM1097_HisHlyA. 
 
4.4.2 Liquid blood lysis assay 
The liquid blood lysis assay was adapted from several previously reported hemolysis 
assays [17-19]. HlyA secreting cells were grown to mid-logarithmic phase in tryptone 
water (1% tryptone, 0.5% NaCl) at 37°C with shaking at 250 rpm. Cultures were 
diluted to OD600 = 0.1 and grown for 1–3 hr at 37°C with shaking at 250 rpm. Cells 
were again diluted to OD600 = 0.1 and centrifuged. The supernatant was removed and 
serially diluted over three orders of magnitude. Sheep erythrocytes (Hardy 
Diagnostics) were washed at least three times in 0.9% sodium chloride by 
centrifugation to remove hemoglobin from lysed cells. A 4% sheep erythrocyte 
suspension was made in 0.9% sodium chloride. Hemolysis was monitored in 96-well 
plates. A reaction buffer was made consisting of 0.9% sodium chloride with 10 mM  
 67 
 
 
 
 
 
 
 
 
 
 
Table 4.1. Table of plasmids and strains used in this study; (A) shows plasmids used 
in the study and their sources (B) shows strains used and their origin. 
 
 
(A)  
Plasmid 
 
Genes 
 
Copy no. 
 
Resistance 
 
Source 
pWAM1097 hlyCA High Ampicillin (Felmlee  et al., 
1985a) 
pWAM716 hlyBD Low chloramphenicol (Felmlee  et al., 
1985b) 
pWAM1097
_HisHlyA 
hlyC, 6X-His 
tagged hlyA 
High Amplicillin This study 
phlyslow hlyC, 6X-His 
tagged hlyA 
High Ampicillin This study (site-
directed 
mutagenesis of 
pWAM1097_HisHl
yA) 
     
 
(B)  Strain 
 
Plasmid 
 
Origin 
W3110 None  
hly-parent pWAM1097_HisHlyA, 
pWAM716 
W3110-based 
hly-slow phlyslow, pWAM716 W3110-based 
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calcium chloride. Each well contained 80 µL of the diluted supernatant, 100 µL 
reaction buffer, and 20 µL of 4% sheep erythrocytes. Diluted supernatants were 
assayed in triplicate. Plates were mixed using the Versamax microplate reader 
(Molecular Devices) for 15 sec to begin the reaction, and then incubated at 37°C. At 
one hour intervals, the plates were mixed for 15 sec, followed by an OD530 
measurement. Undiluted supernatant and tryptone water were used as controls. 
Hemolysis calculations were based on the differences between diluted supernatant 
samples and controls. The predicted dilution required for 50% hemolysis was 
calculated by fitting a line to the slope of the lysis curve.  
 
4.4.3 Vancomycin assay 
This protocol has been adopted [20]. The cells expressing the Type-I secretion system 
were grown in 125 mL culture flasks at 37°C in Luria-Bertani (LB) media 
supplemented with ampicillin (75 µg/mL) and chloramphenicol (85 µg/mL) until they 
reached OD600  = 1. Thereafter, aliquots of cells were taken and incubated at 37°C for 
30 min with mild shaking (200-250 rpm) in the presence of different concentrations of 
vancomycin antibiotic. After vancomycin treatment, cells were plated on LB-agar 
plates in the absence of vancomycin and supplemented with ampicillin (75 µg/mL) 
and chloramphenicol (85 µg/mL). Survival was reported as a percentage of the number 
of colonies formed by control samples previously incubated in the absence of 
vancomycin. 
 
4.4.4 Site-directed mutagenesis 
Primers were obtained from IDT Technologies. The Stratagene QuikChange site-
directed mutagenesis kit was used with a BIORAD icyclerTM thermocycler.   
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Confirmation of the desired changes was obtained by sequencing of purified plasmids 
at DNA services, Cornell University, Ithaca, NY. 
 
4.4.5 Quantitative real time reverse transcription polymerase chain reaction 
(qRT-PCR)  
hlyA mRNA level was evaluated by comparative real-time RT-PCR utilizing 
TaqMan® One-Step RT-PCR Master Mix Reagents Kit (Applied Biosystems) and 
ABI 7900HT Sequence Detection System (Applied Biosystems). HlyA secreting cells 
were grown in 125 ml culture flasks at 37°C in Luria- Bertani (LB) media 
supplemented with ampicillin (75 µg/mL) and chloramphenicol (85 µg/mL) with 
shaking at 250 rpm and total RNA was extracted from the cells using Qiagen RNeasy 
kit (Qiagen), as per the manufacturer’s protocol. 10 ng of total RNA was used for each 
qRT-PCR reaction and 16S rRNA gene was used as an internal control. The hlyA 
specific forward primer 5’-GGTATTCGGCACAGCA GAGAA -3’ and the reverse 
primer  5’-GTCTAATTGTGGTGC AAAGATAGTCACT -3’ and 16S rRNA specific 
forward primer 5’-CCAGCAGCCGCGGTAA T -3’and the reverse primer 5’-
TGCGCTTTACGCCCAGTAAT -3’ were used in these studies. The TaqMan® Probe 
with 6-carboxyfluorescein (6-FAM) as the reporter dye and tetramethyl-6-
carboxyrhodamine (TAMRA) as the quencher was used and the 16S rRNA probe 
sequence was 5’-CCGATTAACGCTTGCACCCTCCG -3’ and hlyA probe sequence was 5’-
CTCATTGGCC TCACCGAACGGG -3’. The threshold cycle for each amplification 
curve was calculated using SDS software, version 2.1 (Applied Biosystems). 
 
4.4.6 Protein fractionation 
Single colonies of the cells transformed with the appropriate plasmids were grown in 
125 ml culture flasks at 37°C in Luria- Bertani (LB) media supplemented with 
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ampicillin (75 µg/mL) and/or chloramphenicol (85 µg/mL). Aliquots of cells were 
harvested at similar OD600 for all the samples and pelleted by centrifugation for 10 
min at 4°C and 4000 × g. 500 µL of the supernatant fraction was transferred to another 
eppendorf tube and mixed with two volumes of ice-cold ethanol. The tubes were left 
overnight at -20°C for protein precipitation and centrifuged next day at 5000 rpm for 
10 min at 4°C. The resulting protein pellets were resuspended in 20 µL of 1X 
phosphate buffered saline (PBS) and analyzed using 1-D SDS-PAGE and western 
blotting. For intracellular protein fractionation from whole cell pellets, the pellets were 
dissolved in 100 µL of SDS sample buffer, heated at 94°C for 10 min, and analyzed 
using SDS-PAGE and western blotting. 
 
4.4.7 Inclusion body preparation 
The protocol has been adopted [21]. Five OD600 units of bacterial cells were 
resuspended in 400 µL of 50 mM Tris (pH 8.0)/1 mM EDTA (hypotonic buffer), 
brought to 0.5 mg/mL lysozyme, and incubated for 5 min at room temperature (RT). 
MgCl2 was added to a final concentration of 5 mM, and the mixture was treated with 
30 units of DNase I for 5 min. Sonication was then carried out at 4°C. Triton X-100 
was added to 0.5%, and the sample was centrifuged at 4°C for 15 min at 14,000 × g. 
The pellet fraction was washed once with 500 µL of buffer A (5% acetonitrile/0.1% 
formic acid) and solubilized with 450 µL of 10M urea/100mM Tris (pH 7.4)/1mM 
Tris (2-carboxyethyl) phosphine at RT for 30 min. Both soluble and inclusion body 
fractions were then analyzed using SDS-PAGE and western blotting. 
 
4.4.7 Western Analysis 
Supernatant fractions and intracellular protein fractions (soluble and inclusion body) 
were resolved by SDS-PAGE (12% w/v) using Tris–HCl and immunoblotted. Mouse 
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anti-6X-His (1:3,000; Sigma) and alkaline phosphatase conjugated goat anti-mouse 
IgG antibody (1:30,000; Sigma) were used as the primary and secondary antibodies 
respectively, for the detection of HlyA protein. Bound antibodies were detected using 
enhanced chemifluorescence (ECF) substrate (GE Amersham Biosciences) following 
the manufacturer’s instructions and imaged using a FLA-3000 Fujifilm scanner. 
Quantitative analysis of the western blots was done using ImageMaster 2D Platinum 
Software v5.0 (GE Amersham Biosciences).  
 
4.5 Results 
There are five nucleotide differences in the hlyA gene in the hly-slow strain relative to 
the hly-parent strain [6]. The five nucleotide changes incorporate rare codons in the 
hly-slow sequence, while keeping the same amino acid sequence. To study the basis 
for increased secretion of HlyA protein in the hly-slow strain (hly-S) compared to hly-
parent strain (hly-P), we considered four possible contributing factors: higher 
expression of hlyA mRNA, higher expression of secretion machinery, more favorable 
external environment, and higher synthesis of protein per mRNA.  
Quantitation of hlyA mRNA in the hly-P and hly-S was performed using comparative 
real time RT-PCR. The 16S rRNA gene sequence was used as an endogenous control 
for this experiment. As seen from the amplification plot (Fig. 4.1), the threshold cycle 
of the 16S rRNA and hlyA mRNA for both hly-P and hly-S overlap with each other in 
the exponential phase of amplification, suggesting that there is no difference in the 
hlyA mRNA expression in the two strains. To test for higher expression of transport 
machinery in the hly-S, we relied on the observation that cells that simultaneously 
express hlyBD and hlyCA are hypersensitive to vancomycin, an antibiotic that is 
relatively inactive against gram-negative bacteria [20]. An increase in sensitivity to 
transport machinery in a given strain. Figure 4.2 shows percentage viable cells for 
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Figure 4.1. Real time RT-PCR to quantify the amount of hlyA mRNA in hly-parent 
(hly-P) and hly-slow (hly-S) strains. 16S rRNA gene was used as an endogenous 
control. The threshold cycle for each amplification curve was calculated using SDS 
software, version 2.1 (Applied Biosystems) and the fold change difference was 
calculated relative to the endogenous control. The fold change in hlyA mRNA 
expression in the two strains was found out to be 0.95. 
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vancomycin would be consistent with elevated expression levels of functional Type-I  
both hly-P and hly-S at different vancomycin concentrations. The data is consistent 
with no significant difference in the number of transporters in the hly-S relative to  
hly-P. 
 
An eight fold increase in secreted HlyA protein activity in hly-S relative to hly-P may 
also result from the over-expression of specific chaperones and/or proteases or any 
other proteins present in the extracellular media, which might affect HlyA protein 
activity or stability. To test whether there is a significant difference between the 
extracellular proteome of the hly-S as compared to the hly-P, we profiled the 
supernatant fractions for both the strains (Fig. 4.3) to identify changes in the secreted 
proteins. The results are qualitatively similar, suggesting that the two strains have 
similar extracellular proteome profile. In this experiment we observed a slight 
decrease in HlyA (identified by mass spectrometry) expression in the supernatant 
fraction of hly-P relative to hly-S, as measured by total protein stain (Fig. 4.3). The 
inconsistent correlation between HlyA protein expression and HlyA activity in hly-S 
relative to hly-P may be attributed to different levels of acylated (active) and non-
acylated (inactive) HlyA in the supernatant fraction of the two strains. Conversion of 
pro-HlyA to the acylated-HlyA (hemolytically active HlyA) takes place in the 
cytoplasm of E. coli and is mediated by HlyC, however HlyC is not required for the 
secretion of pro-HlyA [22]. Hence, the slower translation rate of HlyA in the hly-slow 
strain might result in increased secretion of acylated HlyA relative to the total HlyA  
secretion, resulting in increased activity. Also, the lack of availability of an HlyA 
antibody makes the precise quantitation of HlyA expression difficult. Intracellular 
HlyA protein quantitation was performed to investigate whether there may be more 
HlyA protein synthesis per mRNA molecule in the hly-slow strain relative to the hly- 
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Figure 4.2. Cell viability in the presence of different concentrations of vancomycin 
antibiotic test whether enhanced secretion phenotype is a result of increased 
expression of secretion machinery. The colored bars indicate percentage viable cells of 
hly-parent (hly-P) and hly-slow (hly-S) strains at different concentration of 
vancomycin relative to the cells grown in the absence of vancomycin. W3110 is used 
as a control strain. 
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Figure 4.3. Extracellular proteome profile of hly-parent (hly-P), and hly-slow (hly-S) 
using 1-D SDS-PAGE. The supernatant fractions were collected at similar cell optical 
density (OD600). HlyA protein band (~110 KDa) was confirmed by mass spectrometry 
analysis. 
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parent strain. This experiment was done in hly-parent and hly-slow strains with no 
transport machinery (hlyBD-) to decouple the effects of intracellular protein 
production from secretion. Quantitation of HlyA protein in the cell pellet fractions by 
ECF western analysis (Fig. 4.4) indicates a decrease of about 50% in the intracellular 
level of HlyA protein in the secretion deficient slow strain, hly-S (BD-), relative to the 
secretion deficient parent strain, hly-P (BD-), and is consistent with the 37% predicted 
decrease in translation rate of hlyA gene in hly-slow strain. Soluble and inclusion body 
fractions of HlyA were also measured (Fig.4.4). Nearly all of the HlyA protein is 
present in the inclusion body fraction of the secretion deficient cells, consistent with 
HlyA protein being prone to intracellular protein aggregation. Further, HlyA 
quantitation in the inclusion body fraction by ECF western analysis indicates a 
decrease of about 50% in hly-S (BD-) relative to hly-P (BD-). We also performed 
intracellular HlyA quantitation in secretion competent cells and observed a similar 
decrease in hly-slow (BD+) strain relative to hly-parent (BD+) strain (Fig. 4.5). 
  
A decrease in HlyA protein synthesis rate may result from: (a) enhanced protein 
degradation because of ribosome stalling at the rare codon cluster (SsrA response), (b) 
a significant change in mRNA secondary structure of hly-slow mRNA and/or, (c) 
slower translation due to the presence of a rare codon cluster. It has been suggested in 
the literature that the presence of a stalled ribosome on the mRNA, either due to an 
unwanted stop signal or due to the presence of rare codons, can elicit an SsrA protein 
degradation response in the cell [23]. To test for the effect of the SsrA response, an 
SsrA-defective (W3110 ∆smpB-1, ssrA::kan) strain was transformed with appropriate 
plasmids to create hly-parent (ssrA-) and hly-slow (ssrA-) strains respectively. Both 
intracellular HlyA protein quantitation (in the absence of transport machinery, as 
indicated by hlyBD-) (Fig. 4.5) and HlyA secretion assay (Fig. 4.5) was performed.  
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Figure 4.4. Normalized western blot of intracellular HlyA protein in (a) whole cell 
pellets of secretion deficient strains (BD-), (b) Soluble (S) and inclusion body (I) 
fractions of secretion deficient parent strains, and (c) whole cell pellets of secretion 
competent cells (BD+). An equivalent number of cells were harvested for each 
experiment.  
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Figure 4.5. Intracellular HlyA quantitation and secretion studies in ssrA (-) 
background. (a) Normalized western blot of HlyA protein in whole cell pellets in the 
secretion deficient parent strain, hly-P (BD-) and secretion deficient slow strain, hly-S 
(BD-). (b) Liquid blood assay for secretion competent hly-P and hly-S strains. Each 
reading was performed in triplicate and error bars show the standard deviation of 
triplicate measurements. Fold change calculations were made as follows. The 
supernatant dilution corresponding to 50% hemolysis was calculated (numbers in bold 
marked by red dashed arrows) from the lysis curve and secretion fold change was 
calculated by dividing this dilution. 
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Quantitative western analysis suggests an approximately 50% decrease in the 
intracellular levels of HlyA protein in hly-slow strain relative to hly-parent and liquid 
blood assay indicates approximately a 7.87 fold increase in active HlyA secretion in 
hly-slow strain relative to parent. These results are consistent with the previous 
observations in hly-parent (ssrA+) and hly-slow (ssrA+) strains, suggesting that the 
observed phenotypes (decrease in intracellular HlyA production and increase in 
secreted HlyA activity) are not affected by the SsrA response in the cell.  
 
mRNA secondary structure analysis of hlyA-slow mRNA and hly-parent mRNA was 
also performed using the mRNA secondary structure prediction program, MFOLD 
[24]. Fig. 6 shows the difference in the predicted stem loop structures of the two 
mRNAs. A small Gibb’s free energy difference of 1.09 kcal/mol between the two 
structures. suggests that the translation of the HlyA protein in the hly-slow strain is not 
affected by the change in the hlyA mRNA secondary structure. Hence the decreased 
intracellular HlyA expression in hly-slow strain is likely a result of slower HlyA 
translation rate. 
 
4.6 Discussion 
Differences in codon usage between the source organism and the production host have 
been observed to affect the translation rate of recombinant proteins because codon 
usage directly correlates with the abundance of codon-specific tRNAs available within 
the cell [26]. Generally, a synonymous substitution of the codons in the gene of 
interest to more commonly used codons in the host cell alleviates this problem [27]. 
However, it has been hypothesized that a significant increase in protein expression can 
overwhelm any given secretory pathway [11]. Thus, to achieve high levels of 
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Figure 4.6. The local stem loop mRNA structure of hlyA gene in (a) hly-parent, and 
(b) hly-slow strain, as predicted by the program MFOLD [23]. The figures were 
generated using the program jViz.Rna v1.77 [25]. The differences between the two 
gene sequences are circled and the predicted Gibbs free energy difference between the 
two stem-loop structures is approximately +1.09 kcal/mol.  
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expression and complete processing of the precursor, the translation rate of a  
heterologous protein destined for the secretion pathway requires optimization, not 
simply maximization. We previously demonstrated that a rare codon cluster in the 
target protein (HlyA) gene sequence can lead to an enhanced secretion capability via 
Type-1 secretion machinery [6]. From a mathematical model of translation [14], the 
new hlyA gene sequence has a predicted translation rate decrease of 37% and 
empirically this was achieved by changing five of the adjacent codons to rare codons 
in a specific region of hlyA gene but without altering the amino acid sequence. That 
observation suggests that a balanced synthesis rate is important because too many rare 
codons may not permit enough expression, while too few rare codons may reduce the 
secretion rate by overwhelming the secretory apparatus in the cell. We investigated 
different factors that may account for the enhanced secretion phenotype in the hly-
slow strain and our data suggests that the observed phenotype is the result of 
decreased total HlyA protein production relative to the hly-parent strain. We also 
showed that most of the intracellular HlyA exists in the form of inclusion body 
fraction in secretion incompetent cells. This observation is consistent with the idea that 
intracellular HlyA is mostly unfolded because of the lack of Ca+2 ions, which are 
thought to bind to the RTX repeats in HlyA protein, rich in glycine and aspartic acid 
residues, and initiate HlyA folding [28]. We hypothesize that the HlyA protein 
aggregates might interact with the Type-I translocase to form unwanted protein 
complexes, thereby hindering the transport process.  
 
Another line of hypothesis suggests that there might be secretion competent and 
secretion incompetent pools of substrate protein inside the cell and the introduction of 
rare codons in a specific stretch of the gene of interest can affect the balance of these 
pools and the secretion flux. That is, the type and position of the rare codons 
 82 
introduced may result in populations of different folded/unfolded conformations, 
favoring secretion. Recent studies have shown that the introduction of synonymous 
codon changes in specific regions of the gene of interest can affect the substrate 
specificity of a polypeptide [29,30].  It has been shown that synonymous codon 
substitutions in chloramphenicol acetyltransferase (CAT) gene can affect the CAT 
protein activity during in vitro translation [29]. Also in a recent study, it was shown 
that a certain synonymous codon mutation in the multidrug resistance 1 (MDR1) gene 
in HeLa cells changed the substrate specificity of the MDR1 gene product P-
glycoprotein [30]. Interestingly, the authors in this study hypothesized that the timing 
of folding can be affected by interchanging frequently occurring or abundant codons 
with the rare codons in a specific codon cluster.  
 
To our knowledge, this is the first study which empirically tests the effect of silent 
mutations on the HlyA secretion phenotype. Overall, this study underlines the 
importance of synonymous codon changes in the context of improving HlyA secretion 
yield and may be generalized for the secretion of different recombinant proteins via 
Type-I pathway. We also hypothesize that the effect of rare codons on the HlyA 
secretion yield might be a manifestation of not only the HlyA translation rate, but also 
HlyA folding. 
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CHAPTER-5 
SYNONYMOUS RARE CODON CLUSTER CAN ENHANCE PROTEIN 
SECRETION BY AFFECTING INTERACTION WITH MOLECULAR 
CHAPERONES 
 
 
5.1 Preface 
Silent mutations do not change the amino acid composition of the protein product and 
they have largely been assumed to exert no discernible effect on gene function or 
phenotype. However, recent studies have hinted that synonymous codon replacement 
can change protein folding and activity, indicating that protein structure depends on 
DNA sequence. The following chapter discusses the effect of synonymous rare codon 
cluster on protein folding and secretion in E. coli. 
 
5.2 Abstract 
Synonymous codon substitutions can alter protein folding, structure and function; 
although the mechanism is not well understood. Here, a series of experiments have 
been described to study the effect of synonymous rare codon cluster on protein folding 
and secretion via multiple pathways in E. coli. Significant improvement in the 
secretion of various recombinant proteins by the Type-I, Sec and Tat pathways was 
observed. The analyses revealed that synonymous rare codon cluster at specific sites 
of beta-lactamase gene (bla) can alter folding and subsequent secretion via the Tat 
pathway. We observed that Bla protein expressed with Tat and Type-I secretion signal 
peptides interact with elongation factor (EF-Tu), which may prevent it from folding in 
a secretion competent conformation. Synonymous rare codon substitutions in the 
hemophore gene (hasA) promoted secretion of HasA in a SecB chaperone-independent 
manner, suggesting slower HasA folding. We conclude that synonymous rare codon 
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cluster can enhance protein secretion in E. coli by affecting interactions with 
molecular chaperones.  
 
5.3 Introduction 
Species-specific disparities in codon usage are frequently cited as the cause for 
failures in recombinant gene expression by heterologous hosts. Such failures include a 
lack of expression, expression of a non-functional or insoluble protein, or protein 
truncation due to proteolysis or premature termination translation [1-3]. These 
problems may be overcome by either codon optimization of the target genes [4-8] or 
redesign of genes by substituting the native codons with synonymous codons having 
similar usage frequencies in the expression host [9,10]. It has also been shown that 
synonymous codon changes (specifically replacement of abundant codons by rare 
codons) can significantly improve extracellular secretion in E. coli by reducing 
intracellular aggregates of the recombinant protein [11,12]. These studies suggest that 
synonymous variations in the nucleotide sequence can alter the elongation rate of the 
protein of interest and may impact the fate of the polypeptide during or after the 
process of translation.  
 
In E. coli, as well as in eukaryotes, nascent proteins fold co-translationally within the 
ribosomal tunnel, which is a dynamic environment that influences nascent protein 
structure [13-16]. Hence, subtle variations in the elongation rate may play a key role in 
developing secondary structure in the nascent protein and modulate the folding of the 
translated polypeptide [17]. A recent study has shown that synonymous substitutions 
that introduce rare codons into regions predicted to contain high frequency codons can 
affect substrate specificities [18]. Conversely, synonymous codon substitutions that 
replace rare codons with high frequency codons in regions of slow mRNA translation 
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can deleteriously affect enzyme activity [19,20]. Thus, contrary to conventional 
thinking, synonymous codon substitutions may not always be silent; changing codon 
usage frequency affects protein structure and function, and the frequency with which 
codons are used imparts vital information for the development of secondary and 
tertiary protein structure. 
 
Here, we investigated the effect of silent mutations on protein secretion by the Type-I, 
Sec, Tat and HasABC pathways in E. coli. Significant improvement in extracellular 
and periplasmic secretion of several recombinant proteins was observed by 
synonymous rare codon engineering. Synonymous rare codon cluster at specific sites 
of bla gene altered Bla folding, activity and subsequent secretion via the Tat pathway. 
We observed that Bla protein expressed with the Type-I and Tat signal peptides 
interacts with EF-Tu chaperone and the presence of synonymous rare codon cluster 
can modulate this interaction to increase or inhibit secretion. These results 
demonstrate the utility of synonymous codon engineering in improving protein 
secretion in E. coli and reveal that silent mutations modulate the interactions with 
molecular chaperones and consequently affect protein folding. 
 
5.4 Materials and Methods 
5.4.1 Plasmids and strains 
All primers, plasmids and strains used in this study are shown in Table 5.1. Plasmids 
encoding native IL-6 (IL6), codon optimized IL-6 (coIL6), beta-lactamase (Bla), and 
NYESO1 (ESO1) were fused with the Type-I secretion signal sequence in the 
following manner. The il6 gene was PCR amplified with primers #1 and # 2 using 
pCMV-SPORT6_IL6 plasmid (ATCC number MGC-9215) as the template and the 
HlyA secretion signal sequence (180 bp) was PCR amplified with primers #2 and #3 
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using pWAM1097_HisHlyA as the template. These fragments were ligated and cloned 
Into the HindIII and EcoRI sites of the pEGFP vector (Clontech, CA, USA). The 
codon-optimized il6 gene was custom synthesized with Hind III (5’end) and BglII 
(3’end) restriction sites (BioBasic, Canada) and cloned into similar sites in pEGFP. 
Fusion genes (il6 and coil6 fused with the Type-I signal sequence) were PCR 
amplified with primers # 5 and # 6 (il6) and primers #7 and #6 (coil6) and cloned into 
the NheI and HindIII restriction sites of pWAM1097_HisHlyA to create the 
pWAM1097_IL6 and pWAM1097_coIL6 plasmids. bla and nyeso1 (gift from Ludwig 
Institute for Cancer Research, NY, USA) genes were PCR amplified with primers #8 
and #9 (bla), and primers #10 and #11 (nyeso1) and cloned into the NheI and BglII 
restriction sites of pWAM1097_IL6 to create pWAM1097_coIL6, pWAM1097_bla 
and pWAM1097_ESO1 plasmids. Further, the kanamycin (kan) resistance marker 
gene was PCR amplified with primers #12 and #13 and cloned into the AatII and ScaI 
restriction sites in pWAM1097_Bla to create the pWAM1097kan_Bla plasmid. The 
phasADE plasmid (containing compelete HasA secretion system) was a gift by Cécile 
Wandersman (Institut Pasteur, France) and pTrc99a-cm_Tat-Bla (containing bla gene 
tagged with ssTorA Tat signal peptide) was a gift from Matthew DeLisa (Cornell 
University, USA). pTrc99a-cm_Sec-Bla was created by PCR amplifying the precursor 
bla gene (containing the Sec signal sequence) using primers #14 and #15 and then 
cloning into the SacI and HindIII sites in pTrc99a-cm vector. The gill-bla gene was 
custom synthesized (Genscript, NJ, USA) with NheI (5’end) and BglII (3’end) 
restriction enzyme sites and cloned into similar sites in pWAM1097kan_Bla to make 
pWAM1097kan_gill-bla plasmid. 
 
5.4.2 Site-Directed Mutagenesis 
The synonymous rare codon mutants were first designed in silico using a  
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Table 5.1. (a) plasmids, (b) strains, and (c) primers used in this study. The restriction 
enzyme sites are underlined in the primer sequences. 
 
 
(a)  Plasmid 
 
Genes 
 
Copy no. 
 
Resistance 
 
Source 
 
pWAM716 
 
hlyBD 
 
low 
 
Chloramphenicol 
 
[21] 
 
pWAM1097_
HisHlyA 
 
6X-His 
tagged hlyA 
 
high 
 
Ampicillin 
 
[12] 
phlyM1, 
phlyM2, 
phlyEMut 
HisHlyA high Ampicillin Site directed 
mutagenesis of  
pWAM1097_ 
HisHlyA 
pWAM1097 
kan_Bla 
bla high Kanamycin this study 
pblaM1, 
pblaM2, 
pblaM3 
bla high Kanamycin Site directed 
mutagenesis of  
pWAM1097kan_ 
Bla 
pCMV-
SPOT6_IL6 
il6 high Ampicillin ATCC # MGC-
9215 
pWAM1097_I
L6 
il6 high Ampicillin this study 
pWAM1097 
_coIl6 
coil6 high Ampicillin this study 
pcoil6M1, 
pcoil6M2 
coil6 high Ampicillin Site directed 
mutagenesis of  
pWAM1097_IL6 
pET9a24a-
Syn-NYESO1 
nyeso1 high Kanamycin Gift from Ludwig 
Foundation for 
Cancer Research 
pWAM1097_
ESO1 
nyeso1 high Ampicillin this study 
pesoM1, 
pesoM2, 
pesoM3 
nyeso1 high Ampicillin Site directed 
mutagenesis of  
pWAM1097_ESO1 
pWAM1097k
an_GILL-Bla 
gill-bla high Kanamycin this study 
pgillM1, 
pgillM2, 
pgillM3 
gill-bla high Kanamycin Site directed 
mutagenesis of  
pWAM1097_ 
GILL-Bla 
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Table 5.1 (Continued) 
 
(a)  Plasmid 
 
Genes 
 
Copy no. 
 
Resistance 
 
Source 
 
pTrc99a-cm_ 
Sec-bla 
 
bla tagged 
with Sec 
signal peptide 
 
high 
 
Chloramphenicol 
 
this study 
pSec-blaM1, 
pSec-blaM2, 
pSec-blaM3 
bla tagged 
with Sec 
signal peptide 
high Chloramphenicol Site directed 
mutagenesis of  
pTrc99a-cm_ 
Sec-bla 
pTrc99a-cm_ 
Tat-Bla 
bla tagged 
with Tat 
signal peptide 
(ssTorA) 
high Chloramphenicol [22] 
pTat-blaM1, 
pTat-blaM2, 
pTat-blaM3 
bla tagged 
with Tat 
signal peptide 
high Chloramphenicol Site directed 
mutagenesis of  
pTrc99a-cm_ 
Tat-bla 
phasADE hasADE low Chloramphenicol [23] 
phasM1, 
phasM2 
hasADE low Chloramphenicol Site directed 
mutagenesis of  
phasADE 
 
(b)  Strain 
 
Plasmids 
 
Origin 
 
W3110 
 
None 
 
MC4100 None  
CK1953 None MC4100 
secB::Tn5  [24] 
Hly-parent pWAM1097_HisHlyA, pWAM716 [12] 
Hly-M1 phlyM1, pWAM716 W3110 
Hly-M2 phlyM2, pWAM716 W3110 
Hly-EMut phlyEMut, pWAM716 W3110 
Bla-W pWAM1097kan_Bla, pWAM716 W3110 
Bla-M1 pblaM1, pWAM716 W3110 
Bla-M2 pblaM2, pWAM716 W3110 
Bla-M3 pblaM3, pWAM716 W3110 
coIL6 pWAM1097_coIL6, pWAM716 W3110 
IL6 pWAM1097_IL6, pWAM716 W3110 
coil6M1 pcoil6M1, pWAM716  W3110 
coil6M2 pcoil6M2, pWAM716 W3110 
ESO-W pWAM1097_ESO1, pWAM716 W3110 
ESO-M1 pesoM1, pWAM716 W3110 
ESO-M2 pesoM2, pWAM716 W3110 
 92 
Table 5.1 (continued) 
 
 
(b)  Strain 
 
Plasmids 
 
Origin 
 
ESO-M3 
 
pesoM3, pWAM716 
 
W3110 
 
GILL-W 
 
pWAM1097kan_GILL-Bla, 
pWAM716 
 
W3110 
GILL-M1 pgillM1, pWAM716 W3110 
GILL-M2 pgillM2, pWAM716 W3110 
GILL-M3 pgillM3, pWAM716 W3110 
Sec-W pTrc99a-cm_Sec-bla W3110 
Sec-M1 pSec-blaM1 W3110 
Sec-M2 pSec-blaM2 W3110 
Sec-M3 pSec-blaM3 W3110 
Tat-W pTrc99a-cm_Tat-bla W3110 
Tat-M1 pTat-blaM1 W3110 
Tat-M2 pTat-blaM2 W3110 
Tat-M3 pTat-blaM3 W3110 
Has-W phasADE MC4100 & CK1953 
Has-M1 phasM1 MC4100 & CK1953 
Has-M2 phasM2 MC4100 & CK1953 
 
(c) Primer 
 
Sequence 
 
#1 
 
5’-GCA GAA GCT TGC CAG TAC CCC CAG GAG AAG-3’ 
#2 5’-GAC AGA TCT CAT TTG CCG AAG AGC CCT C-3’ 
#3 5’-GAC AGA TCT TTA GCC TAT GGA AGT CAG G-3’ 
#4 5’-CTG AAT TCT TAT GCT GAT GCT GTC AAA G-3’ 
#5 5’-CAG TGC TAG CAC CAG TAC CCC CAG GAG AAG-3’ 
#6 5’-GCA GAA GCT TTT ATG CTG ATG CTG TCA AAG-3’ 
#7 5’-CAG TGC TAG CAG CGC CGG TTC CGC CGG GTG-3’ 
#8 5’-CAG TGC TAG CAC ACC CAG AAA CGC TGG TGA AAG T-3’     
#9 5’-GTA CAG ATC TCC AAT GCT TAA TCA GTG AGG CAC  
C-3’ 
#10 5’-CAG TGC TAG CAA TGA GAG GAT CGC ATC ACC AT-3’ 
#11 5’-GTA CAG ATC TAC GGC GTT GCC CTG ATG GAG G-3’ 
#12 5’-CCA CAC AGA CGT CGG AAT TGC CAG CTG-3’     
#13 5’-GCA GTA GTA CTT CAG AAG AAC TCG TCA AGA AGG CGA 
TAG-3’ 
#14 5’-GCG ATG GAG CTC ATG AGT ATT CAA CAT TTC CGT GT-
3’ 
#15 5’-ATG GTG AAG CTT TTA CCA ATG CTT AAT CAG TGA  
GGC-3’ 
 93 
mathematical model of translation previously developed [25], which calculates the 
translation rate of the target gene expressed in E. coli. Primers were obtained from 
IDT Technologies (IO, USA). The Stratagene QuikChange II site-directed 
mutagenesis kit (Stratagene, CA, USA) was used per manufacturer’s protocol, with a 
Bio-Rad icyclerTM thermocycler (Bio-Rad, CA, USA). Confirmation of the desired 
changes was obtained by sequencing of purified plasmids at the Cornell 
Biotechnology Resource Center (Cornell University, USA). 
 
5.4.3 Liquid blood lysis assay 
The liquid blood lysis assay was adapted from several previously reported hemolysis 
assays [26,27]. HlyA secreting cells were grown to mid-logarithmic phase in tryptone 
water (1% tryptone, 0.5% NaCl) at 37°C with shaking at 250 rpm. Cultures were 
diluted to OD600 = 0.1 and grown for 1–3 hr at 37°C with shaking at 250 rpm. Cells 
were again diluted to OD600 = 0.1 and centrifuged. The supernatant was removed and 
serially diluted over three orders of magnitude. Sheep erythrocytes (Hardy 
Diagnostics) were washed at least three times in 0.9% sodium chloride by 
centrifugation to remove hemoglobin from lysed cells. A 4% sheep erythrocyte 
suspension was made in 0.9% sodium chloride. Hemolysis was monitored in 96-well 
plates. A reaction buffer was made consisting of 0.9% sodium chloride with 10 mM 
calcium chloride. Each well contained 80 µL of the diluted supernatant, 100 µL 
reaction buffer, and 20 µL of 4% sheep erythrocytes. Diluted supernatants were 
assayed in triplicate. Plates were mixed using a Versamax microplate reader 
(Molecular Devices) for 15 s to begin the reaction, and then incubated at 37°C. At one 
hour intervals, the plates were mixed for 15 s, followed by an OD530 measurement. 
Undiluted supernatant and tryptone water were used as controls. Hemolysis 
calculations were based on the differences between diluted supernatant samples and 
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controls. The predicted dilution required for 50% hemolysis was calculated by fitting a 
line to the slope of the lysis curve.  
 
5.4.4 Protein fractionation and cell growth assay 
Single colonies of the cells transformed with the appropriate plasmids were grown in 
25 ml cultures at 37°C in Luria-Bertani (LB) supplemented with appropriate 
antibiotics (75 µg/mL ampicillin, 50 µg/mL kanamycin, 85 µg/mL chloramphenicol). 
Cells containing HasA plasmids were grown in M9 minimal media containing 
0.1mg/mL thiamine and 0.4% glycerol. Aliquots were harvested at similar OD600 for 
all the samples and pelleted by centrifugation for 10 min at 4°C and 4000 × g. An 
aliquot of 500 µL of the supernatant fraction was transferred to another tube and 
mixed with two volumes of ice-cold ethanol. The tubes were left overnight at -20°C 
for protein precipitation and centrifuged the next day at 5000 rpm for 10 min at 4°C. 
The resulting protein pellets were resuspended in 20 µL of 1X phosphate buffered 
saline (PBS) and analyzed using 1-D SDS-PAGE and Western analysis. For the 
intracellular protein fractionation from whole cell pellets, the pellets were dissolved in 
100 µL of SDS sample buffer, heated at 94°C for 10 min, and analyzed by SDS-PAGE 
and Western. Subcellular fractionation was performed using the ice-cold osmotic 
shock procedure [22,28]. Osmotic shockate (i.e., periplasmic fractions) was assayed 
for beta-lactamase activity based on nitrocefin hydrolysis in 96-well format as 
described elsewhere [29]. Screening of cells on solid plates was performed by 
adopting the method from [30]. Briefly, cells were grown for 6-7 hrs in LB medium 
containing 85 µg/mL chloramphenicol. 5 µL of 10X diluted cells were plated directly 
onto LB agar plates supplemented with 100 µg/mL ampicillin or 85 µg/mL 
chloramphenicol and grown overnight at room temperature.  
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5.4.5 Western Analysis 
Supernatant fractions and intracellular protein fractions (soluble and inclusion body) 
were resolved by SDS–12% (w/v) PAGE using Tris–HCl and immunoblotted. Mouse 
anti-6XHis (1:3,000; Sigma, MO, USA) antibody was used as the primary body for 
the detection of HlyA and NY-ESO-1 because the two proteins contain a N-terminus 
6X-His tag. Anti-HasA antibody was kindly donated by Cécile Wandersman (Institut 
Pasteur, France). Rabbit anti-Bla (1:3000; Millipore, MA, USA) and rabbit anti-hIL-6 
(1:10,000; Sigma, MO, USA) were used for the detection of Bla and hIL-6 
respectively. Secondary antibodies used were goat anti-mouse and goat anti-rabbit 
conjugated with alkaline phosphatase (Sigma, MO, USA) each diluted 1:30,000. 
Bound antibodies were detected by chemifluorescence using ECF Western kit (GE 
Amersham Biosciences, NJ, USA) following manufacturer’s instructions and imaged 
using an FLA-3000 Fujifilm scanner. Quantitative analysis of the Western blots was 
done using ImageMaster 2D Platinum Software v5.0 (GE Amersham Biosciences)  
 
5.4.6 hIL-6 ELISA 
hIL-6 concentrations in the supernatant samples were measured by human IL-6 
Quantikine ELISA kit (R&D Systems, MN, USA), per the manufacturer’s protocol. It 
is a sandwich enzyme-linked immunosorbent assay using a mouse monoclonal capture 
antibody and a polyclonal antibody conjugated to horseradish peroxidase for 
immunodetection of bound IL-6. hIL-6 concentrations in the test samples were 
calculated by linear regression.  
 
5.4.7 Co-Immunoprecipitation (CoIP) 
The protocol was adapted from (ref. 31). An equivalent number of cells were 
harvested and the cytoplasmic fraction was isolated using the ice-cold shock procedure 
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[22,28]. Dynabeads Protein A (Invitrogen, CA, USA) were mixed thoroughly by 
vortexing for 2-3 minutes to obtain a homogenous suspension. 100 µL of the solution 
containing the beads was transferred to a 2 mL tube and the beads were washed three 
times in 500 µl of 0.1 M Na-phosphate buffer (pH 8) and resuspended in 90 µL of the 
same buffer. An appropriate amount of the anti-Bla antibody (Millipore, MA, USA) 
was added to the beads, per manufacturer’s protocol, and the antibody-bead mixture 
was incubated on a rolling platform for 1 hour. The tube was then placed on a magnet 
and the beads were washed 4 times in 500 µL of 0.1 M Na-phosphate buffer (pH 8). 
The cytoplasmic protein fraction was added to the beads and the mixture was 
incubated on the rolling platform for 2 hours at 4 °C. The beads were washed 4 times 
in NETN buffer (20mM Tris (pH 8), 1 mM EDTA, 900 mM NaCl) and then washed in 
NETN buffer containing 100 mM NaCl instead of 900 mM NaCl. The supernatant was 
removed and the beads were subjected to 1-D SDS-PAGE analysis by suspending the 
beads in 100 µL of SDS sample buffer and boiling at 95 °C for 5 mins.  
 
5.4.8 In-gel Digestion and Mass Spectrometry 
Samples were digested and characterized as described elsewhere [32]. Briefly, spots 
were excised using a commercially available 1.5 mm spot cutter (The Gel Company, 
CA, USA). Gel pieces were washed in 50% acetonitrile and digested using the 
ProGest automated digest station (Genomic Solutions Inc., MI, USA) and sequencing 
grade modified trypsin (Promega Corporation,WI, USA). Digests derived from Sypro 
Ruby stained gels were desalted using C18 ZipTips (Millipore, MA, USA). Digest 
samples were spotted onto MALDI plates using the dried droplet method with 1 µL 
digest and 0.5 µL 5 mg/mL α-cyano-4-hydroxycinnamic acid in 50% acetonitrile, 
0.1% trifluroacetic acid. Samples were analyzed using an Applied Biosystems 4800 
Proteomics Analyzer (Applied Biosystems, CA, USA) via matrix assisted laser 
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desorption ionization tandem time-of-flight mass spectrometry (MALDI-TOF/TOF 
MS). Protein identifications were based on a combination of PMF and tandem MS 
spectra. Spectra peaks were searched using Mascot version 2.0 [33] via the GPS 
Explorer software version 3.6 (Applied Biosystems, CA, USA) using NCBInr 
database (last modified 8/15/2006 and available at NCBI www.ncbi.nlm.nih.gov). 
Protein identifications with GPS Explorer confidence interval (C.I.%) scores greater 
than 99% were accepted. For MS/MS spectra, ion C.I.% scores greater than 99% were 
accepted. 
 
5.5 Results 
Synonymous rare codon cluster can enhance secretion of recombinant protein by 
the Type-I pathway. 
The effect of synonymous rare codon clusters on hemolysin (HlyA) secretion by the 
Type-I secretion pathway is tested by making substitutions at different positions. The 
Type-I pathway exports the polypeptides to the extracellular medium and uses a 60 
amino acid C-terminal signal sequence. Previously, it has been shown that a 
synonymous rare codon cluster near the 5’end of the hlyA gene results in an 8-fold 
increase in active HlyA detected in the culture medium [11]. Three other synonymous 
mutants of hlyA gene sequence are expressed, each incorporating a rare codon cluster 
at different positions along the hlyA sequence (Table 5.2). We observe a 9.3-fold and a 
5.8-fold increase in active HlyA secretion in Hly-Mut1 and Hly-Mut2 mutants relative 
to the Hly-parent strain respectively (Fig. 5.1) as measured by a liquid blood lysis 
assay [26,27]. Intracellular HlyA aggregation is decreased by nearly 50% in the Hly-
Mut1 and Hly-Mut2 strains not expressing the HlyBD secretion machinery (Fig. 5.2), 
consistent with the predicted decrease in translation rate. No significant change in 
secreted active HlyA, or in intracellular HlyA in a secretion deficient strain is  
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Table 5.2. Sequence changes (marked in red) and predicted % decrease in translation 
rate of different hly-mutants 
 
 
 
 
 
 
 
 
 
(a) Hly 
Mutants 
Sequence % 
predicted 
Slowdown 
 
hlyM1 1032 CTTGGAT ACGATGGTGA CAGTTTACTT  initial sequence 
     CTAGGGT ACGATGGGGA CAGTCTACTA  rare codon seq. 
 344 L  G  Y   D  G  D   S  L  L    amino acid seq. 
 
39% 
hlyM2 1941 GGTTATC TGACCATTGA TGGCACA     initial sequence 
     GGTTACC TAACCATAGA TGGGACA     rare codon seq. 
 647 G  Y  L   T  I  D   G  T       amino acid seq. 
 
19% 
hlyEMut 1860 AAGGTCT TTTTATCTGC CGGCTCAGCC  initial sequence                                      
     AAGGTCT TTCTATCGGC GGGCTCGGCC  rare codon seq.  
 620 K  V  F   L  S  A   G  S  A    amino acid seq. 
0% 
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Figure 5.1. Effect of synonymous rare codon cluster on HlyA secretion by the Type-I 
pathway. Liquid blood assay for Hly-Mut1, Hly-Mut2, and Hly-EMut strains. Each 
reading performed in triplicate and error bars are the standard deviation of 
measurements. Fold change calculations made as follows. The supernatant dilution 
corresponding to 50% hemolysis is calculated (numbers in bold marked by red dashed 
arrows) from the lysis curve and secretion fold change is calculated by dividing this 
dilution. The table summarizes the change in secretion in the mutants relative to the 
wild-type.
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Figure 5.2 Normalized Western analysis of intracellular HlyA protein (cyto) in 
different hly-mutants. Secretion deficient cells (denoted by BD-) are used for this 
analysis to decouple the effects of intracellular HlyA expression and secretion. An 
equivalent number of cells are harvested and GroEL serves as an intracellular loading 
control. 
 
 
Hly-Parent    Hly-Mut1   Hly-Mut2   Hly-EMut
BD- BD- BD- BD-
HlyA
cyto
GroEL
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observed for Hly-EMut (Fig. 5.1 and 5.2), which has the same predicted translation 
rate relative to the parent hlyA gene. The presence of a synonymous rare codon cluster 
can also affect message stability by modulating mRNA secondary structure [34] and 
an analysis of the difference in the Gibbs free energy of the tested mutant hlyA 
mRNAs relative to parent mRNA indicated no significant change (Table 5.3). 
Comparative RT-PCR measurement of hlyA mRNA levels (Fig. 5.3) demonstrates no 
significant difference either. 
 
To test the observed effect of synonymous changes yielding enhanced secretion, beta-
lactamase (Bla) secretion by the Type-I pathway was also investigated. For this 
experiment, the native signal sequence of Bla protein was replaced by the C-terminal 
Type-I signal sequence. Three synonymous mutants of the bla gene are expressed 
(Table 5.4). Quantitative western analysis reveals a 2.3-fold increase in Bla secretion 
in the Bla-M3 strain that contains the rare codon cluster near the 3’ end of the bla gene 
and has a 21% predicted decrease in the translation rate (Fig. 5.4). The increase in 
extracellular Bla secretion occurs as we observed a decrease in the intracellular Bla 
expression in a secretion deficient strain (Fig. 5.4). As before, no significant change in 
the free energy of the mRNA secondary structures of bla mutants was observed 
relative to the parent bla mRNA (Table 5.3). These observations in HlyA and Bla are 
consistent with the previous finding that decreasing intracellular aggregates result in 
enhanced secretion [12] and suggest that the production of secreted proteins may 
require a balance between translation and secretion. 
 
There are a number of proteins that demonstrate a limited capability for secretion by 
the Type-I pathway. Using the same approach, human interleukin-6 (hIL-6) and testis 
cancer antigen (NY-ESO-1) were tested. For the study of hIL-6 secretion, a codon-  
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Table 5.3. mRNA secondary structure analysis (change in Gibbs free energy) of 
different (a) hlyA-mutants, (b) bla-mutants, (c) il6-mutants, (d) nyeso1-mutants, (e) 
gill-bla mutants, and (f) hasA-mutants relative to the corresponding parent mRNA, as 
predicted by the MFOLD program [35]. 
 
 
 
 
 
 
 
 
 
 
 
(a) Hly-Mutants ∆∆G (kcal/mol) relative to hlyA-parent mRNA 
hlyMut1 -5.97 
hlyMut2 3 
hlyEMut 4.47 
  
(b) Bla-Mutants ∆∆G (kcal/mol) relative to bla-parent mRNA 
blaM1 -0.6 
blaM2 -1.7 
blaM3 -2.7 
  
(c) IL6-Mutants ∆∆G (kcal/mol) relative to coil6-parent mRNA 
Il6 -10.3 
coil6M1 1.9 
coil6M2 1.2 
  
(d) NYESO1-
Mutants 
∆∆G (kcal/mol) relative to nyeso1-parent mRNA 
esoM1 3.5 
esoM2 -1.3 
esoM3 -2.4 
  
(e) GILL-Bla 
Mutants 
∆∆G (kcal/mol) relative to gill-parent mRNA 
gillM1 -3.4 
gillM2 -1.3 
gillM3 -2 
  
(f) HasA-Mutants ∆∆G (kcal/mol) relative to hasA-parent mRNA 
hasM1 2.2 
hasM2 -0.9 
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Figure 5.3. Real time RT-PCR quantifies the amount of hlyA mRNA in different hly 
strains. 16S rRNA gene was used as an endogenous control. 
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Table 5.4. Sequence changes (marked in red) and predicted % decrease in translation 
rate of different bla-mutants 
 
 
 
 
 
 
 
 
 
(b) Bla 
Mutants 
Sequence % 
predicted 
Slowdown 
 
blaM1 195   CTCGGTCGCC GCATACAC       initial seq. 
      CTAGGGAGGA GGATACAC       rare codon seq. 
 65   L  G  R  R   I  H         amino acid seq. 
 
14% 
blaM2 336   CTTCTGACAAC GATCGGAGGA    initial seq. 
      CTACTAACAAC GATAGGGGGA    rare codon seq. 
112   L  T  T   I  G  G         amino acid seq. 
 
13.6% 
blaM3 651   CGCGGTATCA TTGCAGCA       initial seq.  
      AGGGGGATAA TAGCAGCA       rare codon seq. 
217   R  G  I  I   A  A         amino acid seq. 
21% 
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Figure 5.4. Effect of synonymous rare codon cluster on Bla secretion by the Type-I 
pathway Normalized Western analysis of (a) secreted (sup) beta-lactamase (Bla) 
protein, and (b) intracellular Bla protein (cyto) in different bla-mutants. Secretion 
deficient cells (denoted by BD-) are used for this analysis to decouple the effects of 
intracellular Bla expression and secretion. An equivalent number of cells are harvested 
and GroEL serves as an intracellular loading control. 
 
 
Bla sup
Bla-W     Bla-M1    Bla-M2   Bla-M3   
Bla
Bla-W      Bla-M1 Bla-M2   Bla-M3
BD- BD- BD- BD-
GroEL
cyto
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optimized interleukin-6 gene (coil6) with 64 codon changes relative to the native hil6 
gene was synthesized. Based on the coil6 gene sequence, two synonymous mutants 
(coil6M1 and coil6M2) are synthesized with a predicted decrease of 15% and 23% in 
the translation rate relative to the parent gene (coIl6), respectively (Table 5.5). 
Quantitative western analysis as well as ELISA, demonstrate that the IL6 strain 
(containing native il6 having a 7% relative slowdown in translation rate) secretes 8-
fold more IL-6 protein relative to the coIL6 strain (containing coil6 gene) (Fig. 5.5). 
Moreover, a 2-fold and 2.3-fold secretion increase is observed in the coIL6-M1 and 
coIL6-M2 strains, respectively. NY-ESO-1 is a highly immunogenic tumor antigen 
and a promising vaccine candidate in cancer immunotherapy [36] and is not easily 
expressed in bacteria and mammalian cells [37]. Three mutants of nyeso1 are 
synthesized (esoM1, esoM2 and esoM3) with a predicted decrease of 1.9%, 20% and 
15% in the translation rate relative to the nyeso1, respectively (Table 5.6). Quantitative 
western analysis shows a 3-fold and a 5-fold secretion increase in ESO-M2 and ESO-
M3 strains relative to the ESO-W parent strain (Fig. 5.6). Here as well, no significant 
change in the free energy of the mRNA secondary structures of il6 and nyeso1 mutants 
was observed relative to the respective parent mRNA (Table 5.3). Intracellular 
quantitation of hIL-6 and NY-ESO-1 proteins in secretion deficient cells identified an 
elevated expression of the two proteins in the mutant strains relative to the parent 
strain (Fig. 5.5 and 5.6), a trend opposite to the results of HlyA and Bla.  
 
Positional effects of the rare codon cluster on Bla secretion via Type-I pathway. 
The secretion enhancement effect of the synonymous rare codon cluster appears to be 
a function of the type of codon used and the position of the cluster. We investigate the 
positional effects of the synonymous rare codon cluster on Bla secretion by the Type-I 
pathway. A de novo gene sequence based on the bla backbone is designed by  
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Table 5.5. Sequence changes (marked in red) and predicted % decrease in translation 
rate of different il6-mutants  
 
 
 
 
 
 
 
 
 
(c) IL6 
Mutants 
Sequence % 
predicted 
Slowdown 
 
il6 Human Interleukin-6 gene (64 codon changes) 
 
7% 
coil6M1 99   TACATCCTCG ACGGCATCT CAGCC initial sequence 
     TACATCCTAG ACGGGATAT CAGCC rare codon seq. 
33   Y  I  L  D   G  I  S   A   amino acid seq. 
 
15% 
coil6M2 261  GTGAAAATC ATCACTGGT CTTTTG initial sequence 
     GTGAAAATA ATAACTGGG CTATTG rare codon seq. 
 87  V  K  I   I  T  G   L  L   amino acid seq. 
23% 
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Figure 5.5. Secretion of human interleukin-6 (IL-6) protein by the Type-I pathway. (a) 
Normalized Western analysis of secreted IL-6. (b) IL-6 ELISA quantifying the 
amount of secreted IL-6 in different mutants relative to the coIL6 strain. ELISA 
results are consistent with Western analysis. (c) Normalized Western analysis of the 
intracellular IL-6 in secretion deficient cells. An equivalent number of cells are 
harvested. 
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Table 5.6. Sequence changes (marked in red) and predicted % decrease in translation 
rate of different nyeso1-mutants 
 
 
 
 
 
 
 
 
 
(d) 
NYESO1 
Mutants 
 
Sequence 
% 
predicted 
Slowdown 
 
esoM1 87    CCAGGTGGTC CAGGTATCCC A  initial sequence 
      CCAGGTGGGC CCGGGATACC A  rare codon seq. 
29    P  G  G  P   G  I  P     amino acid seq. 
 
1.9% 
esoM2 417   TCCGGCA ACATTCTGAC TATC  initial sequence 
      TCCGGGA ACATACTAAC TATA  rare codon seq. 
139   S  G  N   I  L  T   I    amino acid seq. 
 
20% 
esoM3 462   CGCCAACTGC AGCTCTCCAT C  initial sequence 
      CGCCAACTAC AGCTATCCAT A  rare codon seq. 
154   R  Q  L  Q   L  S  I     amino acid seq. 
15% 
 110 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.6. Secretion of testis cancer antigen protein (NY-ESO1) by the Type-I 
pathway. Normalized Western analysis of (a) secreted NY-ESO1, and (b) intracellular 
NYESO1 in secretion deficient cells (BD-). An equivalent number of cells are 
harvested. 
a
b
ESO-W   ESO-M1   ESO-M2   ESO-M3
NY-ESO1 sup
NY-ESO1 cyto
ESO-W   ESO-M1  ESO-M2  ESO-M3 
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incorporating the codons (GGT ATC CTG CTG), encoding amino acid sequence 
GILL, at three different positions along the bla sequence (Fig. 5.7). Synonymous 
mutants are synthesized by replacing the new codon cluster with the ‘rare’ codon 
cluster (GGG ATA CTA CTA) at each position (Table 5.7). The introduction of these 
changes has no effect on the ability to quantify Bla secretion and intracellular 
expression (Fig. 5.8). Quantitative western analysis of the supernatant fractions 
indicate that GILL-M2 and GILL-M3 strains secrete approximately 1.5-fold and 2-
fold more GILL-Bla protein relative to the parent strain (GILL-W), respectively (Fig. 
5.8). The GILL-M2 and GILL-M3 strains have a 30 % decrease in GILL-Bla 
expression relative to the parent strain in secretion deficient cells (Fig. 5.8). mRNA 
secondary structure analysis of gill-bla mutants shows no significant difference 
relative to parent gill-bla mRNA (Table 5.3). Based on these observations, a rare 
codon cluster near the 3’end of the bla gene has a greater effect on the enhancement of 
secretion by the Type-I pathway compared to a cluster near the 5’ end.  
 
Synonymous rare codon cluster can enhance secretion via the Sec and Tat 
pathways and can also affect polypeptide folding. 
While the effects of a synonymous rare codon cluster clearly alter the Type-I based 
secretion, the possibility exists that this observed phenomenon may be more general 
and can be tested using the general secretion pathway (Sec) and the Tat pathway in E. 
coli. The Sec and Tat pathways use an N-terminal signal peptide and secrete proteins 
into the periplasmic space with the note that Tat pathway is believed to secrete fully 
folded proteins whereas Sec does not. Three synonymous mutants (Table 5.8) were 
synthesized for sec-bla (bla with Sec signal sequence) and tat-bla (bla with Tat signal 
sequence). Cell fractionation [22,28] of different strains tracked the subcellular 
localization of Bla. Quantitative western analysis of the periplasmic fractions of Sec  
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Figure 5.7. Sequence of a de novo gene (gill-bla) to test positional dependence of 
synonymous rare codon cluster on Bla secretion via Type-I pathway. The synonymous 
codon cluster in the new gene (encoding GILL amino acid sequence) is highlighted in 
yellow.
Parent bla gene sequence (795 bp) 
ATGCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGA
ACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTT
TTAAAGTTCTGCTATGTGGCGCGGTATTATCCCGTGTTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATA
CACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGT
AAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCG
GAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATCGTTGGGAA
CCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGCAGCAATGGCAACAACGTT
GCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGG
ATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCC
GGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTAT
CTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGA
TTAAGCATTGGTAA   
 
 
 
Mutant gill-bla gene sequence (801 bp) 
 
ATGCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGA
ACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTT
TTAAAGGTATCCTGCTGTGTGGCGCGGTATTATCCCGTGTTGACGCCGGGCAAGAGCAACTCGGTCGCCGC
ATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGAC
AGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACGGTATCCTGCTGACAA
CGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATCGT
TGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGCAGCAATGGCAAC
AACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGG
AGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCT
GGAGCCGGTGAGCGTGGGTCTCGCGGTATCCTGCTGGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGT
AGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCT
CACTGATTAAGCATTGGTAA 
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Table 5.7. Sequence changes (marked in red) and predicted % decrease in translation 
rate of different gill-bla mutants 
 
 
 
 
 
 
 
 
 
 
(e) GILL-Bla 
Mutants 
Sequence   % predicted 
slowdown 
 
 gillM1 141  AAAGGTA TCCTGCTGTG T  initial sequence   
     AAAGGGA TACTACTATG T  rare codon seq. 
 47  K  G  I   L  L  C     amino acid seq.    
 
5.3% 
gillM2 333  AACGGTA TCCTGCTGAC A  initial sequence   
     AACGGGA TACTACTAAC A  rare codon seq. 
111  N  G  I   L  L  T     amino acid seq. 
 
19% 
gillM3 657  CGCGGTA TCCTGCTGGC A  initial sequence   
     CGCGGGA TACTACTAGC A  rare codon seq. 
219  R  G  I   L  L  A     amino acid seq. 
    10.6%   
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Figure 5.8. Positional effect of rare codon cluster on Bla secretion by the Type-I 
pathway. (a) Design of a de novo gene sequence (gill) based on bla gene sequence. A 
codon cluster (encoding amino acids GILL) is incorporated at three different positions 
along the gene sequence. The new protein (GILL) is detected with anti-Bla serum. 
Normalized Western analysis of GILL in (b) supernatant fraction (sup), and (c) 
intracellular fraction in secretion deficient cells (BD-) (cyto). An equivalent number of 
cells were harvested and GroEL serves as an intracellular loading control.  
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Table 5.8. Sequence changes (marked in red) and predicted % decrease in translation 
rate of different sec-bla and tat-bla mutants 
    
 
 
 
 
 
(b) Sec-Bla 
Mutants 
Sequence % 
predicted 
Slowdown 
 
secM1 261   CTCGGTCGCC GCATACAC     initial seq. 
      CTAGGGAGGA GGATACAC     rare codon seq. 
 87   L  G  R  R   I  H       amino acid seq. 
 
14% 
secM2 402   CTTCTGACAAC GATCGGAGGA  initial seq. 
      CTACTAACAAC GATAGGGGGA  rare codon seq. 
134   L  T  T   I  G  G       amino acid seq. 
 
13.6% 
secM3 717   CGCGGTATCA TTGCAGCA     initial seq.  
      AGGGGGATAA TAGCAGCA     rare codon seq. 
239   R  G  I  I   A  A       amino acid seq. 
21% 
 
 
 
 
 
 
(b) Tat-Bla 
Mutants 
Sequence % 
predicted 
Slowdown 
 
TatM1 348   CTCGGTCGCC GCATACAC     initial seq. 
      CTAGGGAGGA GGATACAC     rare codon seq. 
116   L  G  R  R   I  H       amino acid seq. 
 
14% 
TatM2 489   CTTCTGACAAC GATCGGAGGA  initial seq. 
      CTACTAACAAC GATAGGGGGA  rare codon seq. 
163   L  T  T   I  G  G       amino acid seq. 
 
13.6% 
TatM3 804   CGCGGTATCA TTGCAGCA     initial seq.  
      AGGGGGATAA TAGCAGCA     rare codon seq. 
268   R  G  I  I   A  A       amino acid seq. 
21% 
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strains demonstrates that the Sec-M3 strain secretes 2-fold more Bla protein than the 
Sec-W parent strain (Fig. 5.9). The increase in expression is consistent with an 
increase in Bla activity (Fig. 5.9) and the relative growth levels on solid medium 
containing ampicillin (Amp) (Fig. 5.9). No significant increase in Bla periplasmic 
secretion is observed in the Sec-M1 and Sec-M2 strains (Fig. 5.9). Quantitative 
western analysis of periplasmic fractions of the Tat strains reveals that Tat-M2 
secretes 65% more Bla protein than the parent strain (Tat-W) (Fig. 5.10). However, a 
large unexpected decrease in the periplasmic secretion is observed in the Tat-M1 and 
Tat-M3 strains (Fig. 5.10). Bla activity data and relative growth levels of the strains on 
solid medium containing Amp are consistent with the Western analysis (Fig. 3e and 
3f). A 1.5-fold and a 3-fold increase in cytoplasmic expression of Bla in the Tat-M2 
and Tat-M3 strains relative to the Tat-W strain is also observed (Fig. 5.10). 
Cytoplasmic Bla activity data for Tat-M3 mutant, however, is not consistent with the 
Western analysis and only 20 % of the expressed Bla appears to be active (Fig. 5.10). 
The Tat secretion pathway has a unique ability to discriminate between properly 
folded and misfolded proteins in vivo and secrete only the folded proteins past the 
inner membrane [28,29]. These results suggest that the presence of the rare codon 
cluster at specific positions (Tat-M1 and Tat-M3 but not Tat-M2) can have an affect 
on Bla protein folding and subsequent recognition by the Tat secretion pathway.  
 
Synonymous rare codon cluster affects HasA folding and its interaction with 
SecB chaperone. 
Protein synthesis and folding in E. coli is co-translational [38-40] and the nucleotide 
sequence-dependent modulation of translation kinetics might influence nascent 
polypeptide folding. The HasA hemophore secretion system was used to test the effect 
of a rare codon cluster on polypeptide folding. HasA is a small hemoprotein (188  
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Figure 5.9. Synonymous rare codon cluster affects Bla secretion by the Sec pathway. 
An equivalent number of cells harvested and fractionated into cytoplasmic (cyto) and 
periplasmic (peri) fractions. GroEL serves as a fractionation marker. (a) Normalized 
Western analysis of the periplasmic and cytoplasmic fractions in different Sec strains. 
(b) Bla activity in periplasmic (white bars) and cytoplasmic (grey bars) fractions in 
Sec strains. (c) relative growth of Sec mutants on solid medium by spot plating 5 µL 
of an equivalent number of cells on LB agar supplemented with 100 µg/mL ampicillin 
(Amp) or 85 µg/mL chloramphenicol (Cm). 
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Figure 5.10. Synonymous rare codon cluster affects Bla Tatretion by the Tat pathway. 
An equivalent number of cells harvested and fractionated into cytoplasmic (cyto) and 
periplasmic (peri) fractions. GroEL serves as a fractionation marker. (a) Normalized 
Western analysis of the periplasmic and cytoplasmic fractions in different Tat strains. 
(b) Bla activity in periplasmic (white bars) and cytoplasmic (grey bars) fractions in 
Tat strains. (c) relative growth of Tat mutants on solid medium by spot plating 5 µL of 
an equivalent number of cells on LB agar supplemented with 100 µg/mL ampicillin 
(Amp) or 85 µg/mL chloramphenicol (Cm). 
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amino acids) of Serratia marcescens and is secreted by the dedicated HasA ATP 
binding cassette (ABC) exporter [41.]. The HasA secretion system can be successfully 
reconstituted in E. coli [41] and requires the SecB chaperone, which maintains HasA 
in an unfolded export-competent state [42]. HasA has a very fast folding rate and 
HasA that has folded in the cytoplasm can not be secreted [43,44]. If the synonymous 
rare codon cluster effect is general, then a synonymous rare codon cluster in hasA 
might alter HasA folding enough to permit HasA secretion in the absence of the SecB 
chaperone. Two synonymous mutants (hasM1 and hasM2) were synthesized (Table 
5.9) and have no significant change in the free energy of the mRNA secondary 
structures relative to the parent mRNA (Table 5.3). Quantitative western analysis was 
performed for HasA secretion in secB+ and secB- cells are shown in Figure 5.11. No 
HasA secretion is observed in the parent strain (Has-W), consistent with the previous 
observations [42] (Fig. 5.11). However, the Has-M2 strain secretes HasA in the 
absence of SecB (Fig. 5.11), indicating that the rare codon cluster at this particular site 
alters and enhances the ability of HasA to remain in a secretion competent form. The 
secretion profile of the Has-M1 strain is similar to the parent strain in both genetic 
backgrounds (Fig. 5.11).   
 
Rare codon cluster can affect polypeptide chaperone interactions 
Changes in the translational elongation rate can affect the folding of the preceding 
nascent structural element or its interaction with accessory proteins, within the 
environment of the ribosome tunnel [45]. To test whether the presence of a 
synonymous rare codon cluster can affect the interaction of a polypeptide with a 
molecular chaperone, a co-immunoprecipitation (Co-IP) assay for Bla protein fused 
with the Type-I, Sec and Tat signal peptides was performed. A small number of host 
proteins co-immunoprecipitated with Bla (Fig. 5.12). In the Type-I and Tat secretion  
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Table 5.9. Sequence changes (marked in red) and predicted % decrease in translation 
rate of different hasA-mutants 
 
 
 
 
 
 
 
 
 
 
(f) HasA 
Mutants 
Sequence % predicted 
Slowdown 
 
hasM1 282   GGCGACGGTT TGAGCGGTGGC   initial sequence 
      GGGGACGGGC TAAGCGGGGGC   rare codon seq. 
 94   G  D  G  L   S  G  G     amino acid seq. 
 
36% 
hasM2 345   GGCGGCCTGA ACCTCAGC      initial sequence 
      GGGGGGCTAA ACCTAAGC      rare codon seq. 
115   G  G  L  N   L  S        amino acid seq. 
 40% 
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Figure 5.11. Synonymous rare codon cluster promotes HasA secretion in a  
SecB-independent manner. Normalized Western analysis of secreted and intracellular 
HasA in (a) MC4100 (secB+), and (b) MC4100 (secB-) strains. An equivalent number 
of cells were harvested and GroEL serves as an intracellular loading control. The 
presence of secreted HasA in the supernatant fraction of Has-M2 (secB-) mutant strain 
indicates that the rare codon cluster in hasM2 gene results in slower HasA folding and 
promote the ability to remain in a secretion-competent form.  
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Figure 5.12. Sypro Ruby stained SDS-PAGE gel (a) and corresponding Western 
analysis (b) demonstrates that Bla protein expressed with the Tat signal sequence (Tat-
Bla) can be immunoprecipitated from cell extracts with an anti-Bla antibody. P and M 
refers to precursor and mature beta-lactamase, respectively. Cells that do not express 
Bla protein are used as the negative control (control).  
 
MM          Tat-Bla Control
Tat-Bla Control
Tat-Bla
P
M
a
b
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systems, Bla is found to interact with EF-Tu protein specifically identified by mass 
spectrometry (Fig. 5.13 and 5.14). In contrast EF-Tu did not co-immunoprecipitated 
with the Bla expressed using the Sec signal peptide (Fig. 5.15), demonstrating that EF-
Tu may specifically interact with Bla in a secretion system dependent fashion. 
Previous studies reported that E. coli EF-Tu interacts with the hydrophobic patches of 
the unfolded and denatured proteins and can act as a molecular chaperone [46-49]. 
Here EF-Tu band intensity varied across the tested mutants. The different intensities of 
the EF-Tu band in different Tat samples suggests stronger association of EF-Tu in the 
mutants that secrete less Bla protein (Tat-M1 and Tat-M3) compared to a control (Tat-
W). In contrast, the opposite trend is found for Type-I samples, where a weaker 
association of EF-Tu was observed for the Bla-M3 compared to the control strain 
(Bla-W). These data demonstrate that the synonymous rare codon cluster can alter EF-
Tu interactions with the partially folded nascent Bla polypeptide, resulting in different 
conformations which may be either secretion competent or secretion incompetent.  
 
5.6. Discussion 
Different secretion pathways in E. coli were used to study the effects of synonymous 
substitutions on protein folding and secretion. Type-I secretion studies indicated that 
the synonymous rare codon cluster enhanced protein secretion, whether intracellular 
expression in a secretion deficient cell was decreased (HlyA, Bla) or increased (IL-6, 
NY-ESO-1). These results suggest that the specific effects of synonymous mutations 
may be protein specific and might alter the quality control mechanisms (protein 
aggregation, degradation) triggered by the overexpression of a recombinant protein. 
Increased periplasmic secretion of Bla by the Sec pathway using the synonymous 
codon engineering approach was also observed. Interestingly, for both the Type-I and  
the Sec mechanisms, the Bla mutants (Bla-M3 and Sec-M3), containing the rare codon 
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Figure 5.13. Sypro Ruby stained SDS-PAGE gel demonstrating co-
immunoprecipitated proteins from different Bla strains expressed with the Type-I 
signal sequence. The bold arrow shows co-immunoprecipitated EF-Tu (identified by 
mass spectrometry). All other bands are identified as rabbit albumin, or rabbit IgG. 
MM refers to the molecular marker. 
MM                 Bla-W   Bla-M1   Bla-M2  Bla-M3
EF-Tu42.7
55.6
66.4  
34.6
27
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Figure 5.14. Sypro Ruby stained SDS-PAGE gel demonstrating co-
immunoprecipitated proteins from different Bla strains expressed with the Tat signal 
sequence. The bold arrow shows co-immunoprecipitated EF-Tu (identified by mass 
spectrometry). All other bands are identified as rabbit albumin, or rabbit IgG. MM 
refers to the molecular marker. 
Tat-W   Tat-M1   Tat-M2  Tat-M3               MM       
EF-Tu 42.7
55.6
66.4  
34.6
27
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Figure 5.15. Sypro Ruby stained SDS-PAGE gel demonstrating co-
immunoprecipitated proteins from different Bla mutants expressed with the Sec signal 
sequence. Bands are identified by mass spectrometry as rabbit albumin, rabbit IgG, or 
Bla. No co-immunoprecipitation of EF-Tu protein is observed. 
MM                 Sec-W   Sec-M1   Sec-M2  Sec-M3
42.7
55.6
66.4  
34.6
27
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cluster near the 3’ end, secreted the most protein. It was previously observed that the 
C-terminal end of the Bla protein is essential to its folding and successful transport 
across the inner membrane [50]. While the Sec pathway translocates unfolded proteins 
across the cytoplasmic membrane [51], the Type-I pathway is believed to transport 
polypeptides in a semi-folded conformation [52]. Thus, the presence of the rare codon 
cluster near the 3’ end may slow Bla folding, resulting in a more secretion competent 
polypeptide. 
 
Synonymous rare codon clusters can significantly decrease Bla secretion in the two 
Tat mutants (Tat-M1 and Tat-M3) compared to the parent strain. The existence of a 
folding quality control mechanism is intrinsic to the Tat secretion process [22,53]. 
There appears to be an inconsistent relationship between the cytoplasmic Bla 
expression and activity in the Tat-M3 mutant compared to the parent Tat-W strain, 
consistent with the presence of inactive and secretion incompetent Bla. These results 
suggest that the presence of altered elongation rates resulting from the rare codon 
cluster can change the final protein conformation and activity, as has been observed in 
the intracellular systems not involving secretion [18-20].  
 
The results demonstrate that the synonymous rare codon cluster can alter the 
interaction between the polypeptide, destined for secretion, and molecular chaperones 
which may aid the dynamic in vivo folding of the nascent polypeptide chain into 
different conformations. Surprisingly, the Has-M2 strain secreted HasA in a SecB-
independent manner, suggesting that the synonymous rare codon cluster can alter 
recognition by the HasA transport machinery. Previous studies observed that reduced 
hydrogen bond contacts in the HasA tertiary structure can slow the HasA folding rate 
and reduce the SecB dependence for secretion [54]. That observation is consistent with 
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our finding that modulation of the elongation rates alter the folding behavior and as a 
result, can affect the post-translational fate of the protein. The Bla protein expressed 
with the Tat and Type-I secretion signal peptides interact with the EF-Tu protein 
whereas the Bla protein expressed with the Sec signal peptide did not. The relative EF-
Tu band intensity demonstrates a stronger association of EF-Tu with the Bla 
polypeptide in the strains with decreased secretion for both the Type-I pathway (Bla-
W and Bla-M1 relative to Bla-M3), and the Tat pathway (Tat-M1 and Ta-M3 relative 
to Tat-W). This analysis indicates that the interaction with EF-Tu may result in altered 
local secondary structures which may affect EF-Tu binding to specific sites in the 
polypeptide and prevent it from folding in a secretion competent conformation. 
 
Based on these observations, there may be secretion-competent (SC) and secretion-
incompetent (SI) pools of substrate protein inside the cell and failure to rapidly reach a 
secretion-competent conformation can either result in partial or complete deposition 
into insoluble aggregates or degradation (Fig. 5.16). The introduction of rare codons in 
a specific stretch of the target gene can alter the elongation rate and thus the folding of 
the nascent polypeptide chain enough to change the balance of these pools and 
therefore the secretion observed. In summary, our results offer insights into the 
possible mechanisms of how silent mutations affect protein folding and illustrate the 
utility of synonymous rare codon engineering in improving protein secretion via 
multiple secretion pathways for bioprocess applications. 
 
5.7 Acknowledgements 
We thank Rodney Welch for hemolysin plasmids, Matthew Delisa for pTrc99A-cm  
plasmid and CK1953 strain, Cecille Wandersman for phasADE plasmid and anti- 
HasA antibody, and Ludwig Foundation for Cancer Research for pET9a24a-Syn-NY- 
 129 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.16. Synonymous rare codon cluster affects the balance between secretion 
competent (SC) and secretion incompetent (SI) pools of the protein, destined for 
secretion. 
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CHAPTER-6 
WHOLE-GENOME MUTATIONAL PROFILING REVEALS A SINGLE 
NUCLEOTIDE POLYMORPHISM IN HYPERSECRETER E. COLI 
 
6.1 Preface 
DNA sequencing is a central technology in our understanding of biology and plays a 
significant, supporting role in drug discovery and development. The following chapter 
highlights the promise of short read genome sequencing technology towards rational 
design of interesting phenotypes for biotechnology applications and presents a single 
gene target in E. coli to enhance the extracellular secretion of recombinant proteins in 
E. coli. 
 
6.2 Abstract 
New variant organisms for biotechnology applications can be created by techniques 
like random mutagenesis and adaptive evolution followed by a stringent phenotypic 
selection. However, mutations generated in the process cannot be easily identified 
using traditional genetic tools. Using “next-generation” sequencing technology, a 
parent and a derivative hypersecreter strain (B41) of Escherichia coli W3110 [1] were 
sequenced with an average coverage of 52.8X and 55X, respectively. Mutational 
profiling revealed a single nucleotide polymorphism (G  T) in the B41 genome 
relative to the parent genome at position 1,074,787. This missense mutation results in 
translation termination near the N-terminal end of a transcriptional regulator protein, 
RutR, coded by the ycdC gene [2]. We verified the hypersecretion phenotype in a 
ycdC::Tn5 mutant and observed a 3.4-fold increase in active hemolysin (HlyA) 
secretion relative to the parent strain, consistent with the secretion increase observed 
in B41. mRNA expression profiling showed decreased expression of nearly all tRNA-
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synthetases and some amino acid transporters in the ycdC::Tn5 mutant, suggesting a 
possible role of RutR in the translation process. This study demonstrates the potential 
application of high-throughput massively parallel sequencing technologies to 
characterize selected mutants leading to successful metabolic engineering strategies 
for strain improvement. 
 
6.3 Introduction 
DNA sequencing has contributed to a refined understanding of the molecular basis of 
many fundamental problems of biology. “Next generation” sequencing technologies  
and are being used extensively to understand disease association [3-5], drug 
resistance6, biomarkers [7-9], and develop molecular diagnostics [10,11]. From a 
biotechnology standpoint, the use of these technologies to understand the genomic 
basis for interesting phenotypes can accelerate strain improvement by providing 
precise targets for metabolic engineering. Additionally, these technologies can be used 
in tandem with “–omics” tools to gain insights into specific gene functions. 
Previously, a hypersecreting E. coli strain (B41) was created by chemical mutagenesis 
of the parent strain and was found to secrete four-fold more hemolysin (HlyA) protein 
relative to the parent strain via the Type-I secretion pathway [2]. The genomic DNA 
mutations generated in the process, however could not be identified because of 
technological limitation at that time. In this study, we used short read sequencing 
technology to reveal a single nucleotide polymorphism (SNP) in the B41 genome 
relative to the parent genome. mRNA expression profiling of the ycdC::Tn5 mutant 
and the parent strain is performed to understand the basis of the hypersecretion 
phenotype in the mutant strain. This study presents a single gene target in E. coli to 
enhance the extracellular secretion of recombinant proteins and illustrates the promise 
of genome sequencing towards rational design of interesting phenotypes for 
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biotechnology applications. 
 
6.4 Materials and Methods 
6.4.1 Plasmids and strains  
All plasmids and strains used in this study are shown in Table 6.1. Plasmid 
pWAM1097kan_Bla was created as follows. First bla gene was PCR amplified with 
primers (5’- GCA GAA GCT TGC ACC CAG AAA CGC TGG TGA AAG T -3’ and 
5’- GAC AGA TCT CCA ATG CTT AAT CAG TGA GGC -3’) incorporating 
HindIII restriction site at the 5’end and BglII restriction site at the 3’ end and HlyA 
secretion signal sequence (180 bp) was PCR amplified with primers (5’- GAC AGA 
TCT  TTA GCC TAT GGA AGT CAG G -3’ and 5’- CTG AAT TCT TAT GCT 
GAT GCT GTC AAA G -3’) incorporating BglII restriction site at the 5’end and 
EcoRI restriction site at the 3’ end. These fragments were ligated and then cloned into 
HindIII and EcoRI sites of pEGFP vector (Clontech, CA, USA). The fusion gene 
sequences were then PCR amplified with primers (5’- CAG TGC TAG CAC ACC 
CAG AAA CGC TGG TGA AAG T -3’ and 5’- GCA GAA GCT TTT ATG CTG 
ATG CTG TCA AAG -3’) incorporating NheI restriction site at the 5’end and HindIII 
restriction site at the 3’ end and cloned into the same sites of pWAM1097_HisHlyA to 
make pWAM1097_Bla. Finally, kanamycin (kan) resistant marker gene was PCR 
amplified with primers (5’- CCA CAC AGA CGT CGG AAT TGC CAG CTG -3’ 
and 5’- GCA GTA GTA CTT CAG AAG AAC TCG TCA AGA AGG CGA TAG -
3’) incorporating AatII (5’end) and ScaI (3’end) restriction enzyme sites and then 
cloned into similar sites in pWAM1097_Bla to create pWAM1097kan_Bla plasmid. 
The plasmids were then transformed with or without pWAM716 (encoding Type-I 
secretion machinery) in FB22271 (MG1655ycdC::Tn5) and MG1655 cells to create 
appropriate strains. 
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Table 6.1. Table of plasmids and strains used in this study; (A) shows plasmids used 
in the study and their sources (B) shows strains used and their origin. 
 
 
(A)  Plasmid 
 
Genes 
 
Copy no. 
 
Resistance 
 
Source 
pWAM716 hlyBD low Chloramphenicol [12] 
pWAM1097 hlyCA high Ampicillin [13] 
pWAM1097_HisHlyA hlyC, 6X-His 
tagged hlyA 
high Ampicillin [14] 
pWAM1097kan_Bla Bla high Kanamycin This 
study 
     
 
(B)  Strain 
 
Plasmid 
 
Origin 
W3110 None  
MG1655 None (E. coli K-12 MG1655 
Genome Initiative) 
FB22271 None MG1655 ycdc::Tn5  E. coli 
K-12 MG1655 Genome 
Initiative) 
Hly-parent pWAM1097, pWAM716 W3110-based [1] 
B41 pWAM1097, pWAM716 W3110-based [1] 
Hly-ycdC+ pWAM1097_HisHlyA, 
pWAM716 
MG1655-based (this study) 
Hly-ycdC- pWAM1097_HisHlyA, 
pWAM716 
FB22271-based (this study) 
Hly-ycdC+ (BD-) pWAM1097_HisHlyA MG1655-based (this study) 
Hly-ycdC- (BD-) pWAM1097_HisHlyA FB22271-based (this study) 
Bla-ycdC+  pWAM1097kan_Bla, 
pWAM716 
MG1655-based (this study) 
Bla-ycdC- pWAM1097kan_Bla, 
pWAM716 
FB22271-based (this study) 
Bla-ycdC+ (BD-) pWAM1097kan_Bla MG1655-based (this study) 
Bla-ycdC- (BD-) pWAM1097kan_Bla FB22271-based (this study) 
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6.4.2 Genome sequencing and analysis 
Genomic DNA of hly-parent and B41 strains was isolated using GenElute Bacterial 
Genomic DNA Kit (Sigma, MO, USA), according to manufacturer’s instructions and 
the samples were sequenced in duplicates. Genome sequencing was performed and 
analyzed with a Illumina Genome AnalyzerTM (Illumina, CA, USA) at Cornell 
University Life Sciences Core Laboratories Center. Briefly, 5 µg of genomic DNA 
was fragmented below 800 bp using a nebulizer and end-repaired with T4 DNA 
polymerase. A single dA was added to the ends using Klenow fragment and dATP. 
Fragments were then ligated with adaptors provided by the manufacturer. Adaptor 
ligated fragments were separated from unligated adaptors by running an agarose gel 
and cutting a band corresponding to 150–200 bp and purified using a spin column. The 
fragment library containing adaptors was subjected to 10 rounds of PCR using primers 
supplied by Illumina. This amplified library was then loaded onto the cluster 
generation station for single molecule bridge amplification on slides containing 
attached primers. The slide with amplified clusters was then subjected to step-wise 
sequencing using four-color labeled nucleotides on the Illumina Genome Analyzer II 
for 36 cycles. A total of 15,638,760 read sequences were obtained after quality 
filtering.W3110 genome sequence (Genbank accession number AP009048) was used 
as the reference genome to align the sequences of the two genomes. Alignment was 
accomplished using the Eland program (Illumina, CA, USA) and up to two 
mismatches were allowed per read. Reads that did not align to the genome uniquely 
were discarded. An SNP detection program was written in Java (Sun Microsystems, 
CA, USA). The numbers of correctly aligned and mismatched base pairs at each 
position were used to generate a mismatch percentage. The difference in mismatch 
percentages at each position in the two alignments was used to detect SNPs. 
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6.4.3 Quantitative real time reverse transcription polymerase chain reaction 
(qRT-PCR)  
hlyA mRNA level was evaluated by comparative real-time RT-PCR utilizing 
TaqMan® One-Step RT-PCR Master Mix Reagents Kit and ABI 7900HT Sequence 
Detection System (Applied Biosystems, CA, USA). Total RNA was extracted from 
the cells using Qiagen RNeasy kit (Qiagen, CA, USA), as per the manufacturer’s 
protocol and 10 ng of total RNA was used for each reaction. 16S rRNA gene was used 
as an internal control. The hlyA specific forward primer 5’-GGT ATT CGG CAC 
AGC AGA GAA -3’ and the reverse primer  5’-GTC TAA TTG TGG TGC AAA 
GAT AGT CAC T -3’ and 16S rRNA specific forward primer 5’-CCA GCA GCC 
GCG GTA AT -3’and the reverse primer 5’-TGC GCT TTA CGC CCA GTA AT -3’ 
were used in these studies. The TaqMan® Probe with 6-carboxyfluorescein (6-FAM) 
as the reporter dye and tetramethyl-6-carboxyrhodamine (TAMRA) as the quencher 
was used and the 16S rRNA probe sequence was 5’-CCG ATT AAC GCT TGC ACC CTC 
CG -3’ and hlyA probe sequence was 5’-CTC ATT GGC CTC ACC GAA CGG G -3’. 
The threshold cycle for each amplification curve was calculated using SDS software, 
version 2.1 (Applied Biosystems, CA, USA). 
 
6.4.4 Vancomycin assay 
This protocol is adapted from a published study [15]. The cells expressing the Type-I 
secretion system were grown in 25 mL cultures at 37°C in Luria- Bertani (LB) 
supplemented with ampicillin (75 µg/mL) and chloramphenicol (85 µg/mL) until they 
reached OD600  = 1. Thereafter, aliquots of cells were taken and incubated at 37°C for 
30 min with mild shaking (200-250 rpm) in the presence of different concentrations of 
vancomycin antibiotic. After vancomycin treatment, cells were plated on LB-agar 
plates in the absence of vancomycin and supplemented with ampicillin (75 µg/mL) 
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and chloramphenicol (85 µg/mL). Survival was reported as a percentage of the number 
of colonies formed by control samples previously incubated in the absence of 
vancomycin. 
 
6.4.5 Liquid blood lysis assay 
The liquid blood lysis assay was adapted from previously reported hemolysis assay 
protocols [16,17]. HlyA secreting cells were grown to mid-logarithmic phase in 
tryptone water (1% tryptone, 0.5% NaCl) at 37°C with shaking at 250 rpm. Cultures 
were diluted to OD600 = 0.1 and grown for 1–3 hr at 37°C with shaking at 250 rpm. 
Cells were again diluted to OD600 = 0.1 and centrifuged. The supernatant was removed 
and serially diluted over three orders of magnitude. Sheep erythrocytes (Hardy 
Diagnostics, CA, USA) were washed at least three times in 0.9% sodium chloride by 
centrifugation to remove hemoglobin from lysed cells. A 4% sheep erythrocyte 
suspension was made in 0.9% sodium chloride. Hemolysis was monitored in 96-well 
plates. A reaction buffer was made consisting of 0.9% sodium chloride with 10 mM 
calcium chloride. Each well contained 80 µL of the diluted supernatant, 100 µL 
reaction buffer, and 20 µL of 4% sheep erythrocytes. Diluted supernatants were 
assayed in triplicate. Plates were mixed using the Versamax microplate reader 
(Molecular Devices) for 15 s to begin the reaction, and then incubated at 37°C. At one 
hour intervals, the plates were mixed for 15 s, followed by an OD530 measurement. 
Undiluted supernatant and tryptone water were used as controls. Hemolysis 
calculations were based on the differences between diluted supernatant samples and 
controls. The predicted dilution required for 50% hemolysis was calculated by fitting a 
line to the slope of the lysis curve.  
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6.4.6 Protein fractionation 
Single colonies of the cells transformed with the appropriate plasmids were grown in 
25 ml cultures at 37°C in Luria- Bertani (LB) supplemented with appropriate 
antibiotics (ampicillin (75 µg/mL), kanamycin (30 µg/mL), chloramphenicol (85 
µg/mL)). Aliquots of cells were harvested at similar OD600 for all the samples and 
pelleted by centrifugation for 10 min at 4°C and 4000 × g. 500 µL of the supernatant 
fraction was transferred to another eppendorf tube and mixed with two volumes of ice-
cold ethanol. The tubes were left overnight at -20°C for protein precipitation and 
centrifuged next day at 5000 rpm for 10 min at 4°C. The resulting protein pellets were 
resuspended in 20 µL of 1X phosphate buffered saline (PBS) and analyzed using 1-D 
SDS-PAGE and western blotting. For intracellular protein fractionation from whole 
cell pellets, the pellets were dissolved in 100 µL of SDS sample buffer, heated at 94°C 
for 10 min, and analyzed using SDS-PAGE and western blotting. 
 
6.4.7 Western Analysis 
Supernatant fractions and intracellular protein fractions (soluble and inclusion body) 
were resolved by SDS-PAGE (12% w/v) using Tris–HCl and immunoblotted. Mouse 
anti-6X-His (Sigma, MO, USA; 1:3000) and rabbit anti-Bla (Millipore, MA, USA; 
1:3000) were used as primary antibodies and alkaline phosphatase conjugated goat 
anti-mouse IgG antibody (Sigma, MO, USA; 1:30,000) and anti-rabbit IgG antibody 
(Sigma, MO, USA; 1:30,000) were used as secondary antibodies for the detection of 
respective proteins. Bound antibodies were detected using enhanced 
chemifluorescence (ECF) substrate (GE Amersham Biosciences, NJ, USA) following 
the manufacturer’s instructions and imaged using a FLA-3000 Fujifilm scanner. 
Quantitative analysis of the western blots was done using ImageMaster 2D Platinum 
Software v5.0 (GE Amersham Biosciences, NJ, USA).  
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6.4.8 mRNA Isolation and GeneChip Analysis 
Three biological replicate cultures for each strain were harvested at a mid-exponential 
phase and were resuspended in two volumes of RNAprotect Bacterial Reagent 
(Qiagen, CA, USA). Total RNA was extracted from the cells using Qiagen RNeasy kit 
(Qiagen, CA, USA), as per the manufacturer’s protocol. RNase-Free DNase kit 
(Qiagen, CA, USA) was also used to minimize the genomic DNA contamination. 
RNA samples were processed according to the Affymetrix prokaryotic sample and 
array processing protocol. Briefly, cDNA fragments were generated from RNA 
samples via reverse transcription using random hexamer primers. The resulting cDNA 
was then fluorescently labeled and hybridized to GeneChip E. coli Genome 2.0 Array 
(Affymetrix, CA, USA) and the arrays were scanned at the Cornell University Life 
Sciences Core Laboratories Center. Probe intensity data from scanned chip images 
were normalized using a RMA procedure and analyzed using GeneSpringTM software 
(Agilent, CA, USA). The fold change in gene expression was calculated by comparing 
mRNA expression values across the two strains. Unpaired t-test with P ≤ 0.1 was used 
to identify the genes with statistically significant expression change. 
 
6.5 Results and Discussions 
B41 and Hly-parent genomes were sequenced using the Illumina genome analyzer. 
The sequence fragments were aligned to the W3110 E. coli genome (Genbank 
accession number AP009048) using the Eland program (Illumina), which allows up to 
two base pair (bp) mismatches between each 32 bp sequence fragment and the W3110 
genome. The average depth of sequence coverage for the Hly-parent and B41 genomes 
was found to be 52.8X and 55.0X, respectively (Fig. 6.1). For each alignment, 97.5% 
of the published W3110 genome was covered by 8 sequence fragments or more. A 
base pair caller program was developed in JavaTM (Sun Microsystems, CA, USA) to  
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Figure 6.1. Genome coverage of W3110 E. coli from Illumina sequence data. The x-
axis denotes the sequence coverage depth and the y-axis shows the percentage of E. 
coli genome covered by each of the two alignments. Duplicate samples of Hly parent 
and B41 genomes were sequenced and analyzed.  
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detect single nucleotide polymorphisms. The percentage of mismatched base pairs was 
recorded at each position in the W3110 genome. A log plot histogram detailing the 
frequency of mismatch percentages throughout the genome is shown in Figure 6.2.  
99.99% of the covered genome had a mismatch percentage of 20% or less. To detect 
mutations, the percent of mismatches at each position in the genome from Hly-parent 
and B41 strains were compared and the ten positions with the greatest difference were 
identified (Fig. 6.3). Positions with a large difference in the mismatch percentage 
represent probable polymorphisms between the B41 mutant and Hly-parent. The 
single nucleotide polymorphism (SNP) detected at position 1,074,787 has 100% 
difference in the mismatch rate between the B41 and Hly-parent alignments and was 
present in all 49 sequence reads from both B41 samples and none of the 58 sequence 
reads from the two Hly-parent samples (Fig.6.4). All other positions had a mismatch 
percentage difference of 30% or less (Fig. 6.3). The SNP (at position 1,074,787) 
results in a guanine to thymine mutation in the ycdC gene (at position 124 bp relative 
to the translation start site), which prematurely terminates the translation of RutR 
protein, a recently discovered transcriptional repressor of the pyrimidine utilization 
pathway (rut pathway) [2].   
 
To understand how the absence of RutR increases active HlyA secretion in the B41 
strain, three possible contributing factors were considered: higher expression of hlyA 
mRNA, higher expression of Type-I secretion machinery, and secretion of accessory 
proteins that may affect HlyA activity and stability. No significant difference in hlyA 
mRNA levels in the Hly-parent and B41 strains was observed by comparative real 
time RT-PCR (Fig. 6.5). To test for higher expression of transport machinery in the 
B41 strain, we relied on the observation that cells that express Type-I secretion 
machinery are hypersensitive to vancomycin, an antibiotic that is relatively inactive  
 147 
     
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
Figure 6.2. Distribution of mismatch percentages across the Hly parent and B41 
genomes in log scale. The x axis shows percentages of aligned base pairs that do not 
match W3110 genome. Aligned fragments covered 97.3% of the W3110 genome.  
99.99% of the covered portion of the genome had a mismatch percentage under 20%. 
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Figure 6.3. Percent differences of mismatched bases between Hly parent and B41 
genomes. The positions with the ten largest values are displayed. A difference of 1 
occurs when all the base pairs at a certain position in B41 genome do not match and 
all the base pairs at a certain position in Hly-parent genome match the W3110 
genome. 
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Figure 6.4. Sequence data from Hly parent and B41 genomes illustrating the presence 
of single nucleotide polymorphism in B41 genome. The mutation (GT) was present 
in all 49 sequence reads from both B41 samples and none of the 58 sequence reads 
from the two hly-P samples. The underlined set of nucleotides is the reference W3110 
genome and the arrow indicates the position of the SNP in the B41 mutant relative to 
the Hly-parent.  
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Figure 6.5. Real time RT-PCR to quantify the amount of hlyA mRNA in Hly parent 
and B41 strains. 16S rRNA gene was used as an endogenous control. The fold change 
in hlyA mRNA expression in the two strains was found out to be 0.98. 
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against gram-negative bacteria [18]. Increased vancomycin sensitivity is consistent 
with elevated expression levels of functional Type-I transport machinery [15]. No 
significant difference in cell viability was observed between the Hly-parent and B41 
strains (Fig. 6.6), consistent with no significant difference in the number of Type-I 
transporters in the two strains. Finally, extracellular proteomes of the Hly-parent and 
B41 strains were compared by profiling their supernatant fractions to identify changes 
in the secreted proteins (Fig. 6.7). The results are qualitatively similar, suggesting that 
the two strains have similar extracellular proteome profiles.  
 
The absence of functional RutR might also affect the relative HlyA protein expression 
in the two strains. To measure the intracellular HlyA expression, a 6X-His tag was 
cloned at the N-terminal end of HlyA protein. The activity level of 6X-His tagged 
HlyA was found to be similar to HlyA (Fig. 6.8). Secretion and intracellular HlyA 
quantitation studies were then performed in a ycdC negative background. Appropriate 
Hly-plasmids (pWAM1097_HisHlyA, pWAM716) were transformed in FB22271 
(MG1655 based strain containing a ycdC::Tn5 lesion) and parent MG1655 strains to 
construct Hly-ycdC- and Hly-ycdC+ strains respectively. A 3.4-fold increase in HlyA 
secretion was observed in the Hly-ycdC- strain relative to the Hly-ycdC+ strain by 
western blotting (Fig. 6.9). The increase in active HlyA secretion was also confirmed 
by a liquid blood lysis assay (Fig. 6.9) and is consistent with the increased secretion 
observed in the B41 strain [1]. Intracellular HlyA quantitation was performed in 
secretion deficient ycdC- and ycdC+ strains (denoted by Hly-ycdC- (BD-) and Hly-
ycdC+ (BD-)) to decouple the effects of secretion and HlyA protein production. 
Western analysis indicated a 23% decrease in HlyA protein expression in the Hly-
ycdC- (BD-) relative to Hly-ycdC+ (BD-) strain (Fig. 6.10). We also examined the 
secretion of beta-lactamase (Bla via the Type-I secretion pathway in a ycdC negative  
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Figure 6.6. Cell viability in the presence of different concentrations of vancomycin 
antibiotic test whether enhanced secretion phenotype is a result of increased 
expression of secretion machinery. The colored bars indicate percentage of viable cells 
of Hly-parent and B41 strains at different concentration of vancomycin relative to the 
cells grown in the absence of vancomycin. W3110 is used as a control strain. 
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Figure 6.7. Extracellular proteome profile of Hly-parent and B41 strains using 1-D 
SDS-PAGE. The supernatant fractions were collected at similar cell optical density 
(OD600). HlyA protein band (~110 KDa) was confirmed by mass spectrometry 
analysis. 
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Figure 6.8. 6X-His tagged HlyA has similar activity as HlyA as quantified by liquid 
blood lysis assay (a). The supernatant dilution corresponding to 50% hemolysis was 
calculated (numbers in bold marked by blue dashed arrows) from the lysis curve and 
secretion fold change was calculated by taking the ratio of the dilutions. (b) Western 
blot analysis of the supernatant fraction indicates that mouse anti-6X-His antibody 
(Sigma, MO, USA) interacts preferentially with the 6X-His tag on HlyA protein and 
not with secreted HlyA itself. 
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Figure 6.9. (a) Liquid blood lysis assay to quantify the amount of secreted active HlyA 
protein in Hly-ycdC+ and Hly-ycdC- strains. Each reading was performed in triplicates 
and error bars show the standard deviation of triplicate measurements. The supernatant 
dilution corresponding to 50% hemolysis was calculated (numbers in bold marked by 
blue dashed arrows) from the lysis curve and secretion fold change was calculated by 
taking the ratio of the dilutions. (b) The 3.4-fold increase in HlyA secretion was also 
verified by normalized western blot analysis of the secreted HlyA protein. 
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Figure 6.10. Normalized western blot analysis of intracellular HlyA protein in the 
secretion deficient strains, Hly-ycdC+ (BD-) and Hly-ycdC- (BD-). Secretion deficient 
strains were used to decouple the effects of secretion and intracellular protein 
production. Samples were normalized on the basis of cell density and quantitative 
analysis of the western blots was done using ImageMaster 2D Platinum Software v5.0 
(GE Amersham Biosciences, NJ, USA). 
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background. Western blot analysis of the supernatant fractions indicates a 42% 
increase in Bla secretion in the Bla-ycdC- relative to Bla-ycdC+ strain (Fig. 6.11). 
Intracellular quantitation of Bla in secretion deficient cells revealed a 30% decreased 
expression in the Bla-ycdC- (BD-) strain relative to Bla-ycdC+ (BD-) strain (Figure 
6.11). We previously observed that decreased HlyA expression can result in active 
HlyA hypersecretion [14], and it has been hypothesized that a significant increase in 
protein expression can overwhelm the secretory pathway [18]. Hence, we 
hypothesized that the absence of functional RutR (coded by ycdC gene) may increase 
active HlyA secretion by decreasing the HlyA translation rate and promoting a balance 
between HlyA translation and secretion.  
 
To further investigate the effect of the absence of functional RutR on HlyA translation 
rate, mRNA expression profiling of Hly-ycdC- and Hly-ycdC+ strains was performed 
using Affymetrix GeneChip E. coli Genome 2.0 array. Gene expression analysis, 
using GeneSpringTM software (Agilent, CA, USA), detected 240 genes that are 
differentially expressed in the two strains. The data are presented as absolute ratios of 
the normalized gene expression between the Hly-ycdC- and Hly-ycdC+ strains. Values 
greater than 1.0 indicate that the gene was expressed more highly in the Hly-ycdC- 
mutant and values less than 1.0 indicate a lower expression level in the Hly-ycdC- 
mutant. Expression of the carbamoylphosphate synthase (CarAB) small subunit gene 
(carA) was decreased 2.36-fold in the Hly-ycdC- mutant relative to the Hly-ycdC+ 
strain (Table 6.2), consistent with a recent study which showed that RutR is a positive 
regulator of the carAB operon [19]. CarAB utilizes glutamine as the natural amino 
group donor and provides carbamoylphosphate for arginine and pyrimidine 
biosynthesis [20,21]. Arginine biosynthesis was shown to be interlinked with proline 
biosynthesis via early intermediates in the two pathways [22]. Thus, decreased carA  
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Figure 6.11. Absence of a functional ycdC increases the secretion of beta-lactamase 
(Bla) protein. Normalized western blot of (a) extracellular Bla expression (sup) in 
ycdC+ and ycdC-strains, and (b) intracellular Bla expression (cyto) in secretion 
deficient ycdC+ (BD-) and ycdC- (BD-) strains. Samples were normalized on the basis 
of cell density and quantitative analysis of the western blots was done using 
ImageMaster 2D Platinum Software v5.0 (GE Amersham Biosciences, NJ, USA).
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Table 6.2. mRNA fold change levels of carA and amino acid transporter genes for 
proline, arginine, tyrosine and histidine in the Hly-ycdC- mutant relative to the Hly-
ycdC+ strain. Values less than 1.0 indicate a lower expression level in the hly-ycdC- 
mutant and vice versa. 
 
 
 
 
 
 
Gene 
Name Gene Title 
Fold change  
(Hly-ycdC¯ / Hly-
ycdC+) 
carA carbamoyl phosphate synthase small subunit 0.42 
proY proline permease transport protein  0.82 
putP Proline:sodium symporter 0.87 
artJ arginine transporter subunit 0.71 
tyrP tyrosine-specific transport protein 0.61 
hisM 
histidine transport system membrane protein 
M 0.62 
hisQ 
histidine transport system permease protein 
hisQ 0.69 
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expression might have a cascade effect on these biosynthetic pathways resulting in 
decreased intracellular levels of arginine and proline. We also observed a decreased 
expression of amino acid transporter genes for arginine, proline, tyrosine and histidine 
in the Hly- ycdC- mutant (Table 6.2), which suggests a decreased import of the 
respective amino acids present in the extracellular media. Also, the mRNA levels of 
tRNA-synthetase genes were found to be either decreased or unchanged in the Hly-
ycdC- strain relative to the Hly-ycdC+ strain (Table 6.3), consistent with our previous 
observation in B41 strain1. This genome-wide analysis reveals that RutR protein play 
an important role in maintaining the balance of various substrates (amino acids, tRNA-
synthetases) of the E. coli translation machinery and the absence of functional RutR 
may result in slower translation rates of proteins, and in particular recombinant HlyA. 
This premise is consistent with our observation that there is a decreased intracellular 
HlyA and Bla expression in secretion deficient strains (Fig. 6.10 and 6.11).  
 
6.6 Conclusion 
In this study, we report the discovery of a single nucleotide polymorphism (G  T) in 
the hypersecreter B41 genome relative to the Hly-parent genome. Different factors 
that may account for the effect of the SNP on HlyA secretion phenotype were 
investigated and our data suggests that the absence of functional RutR resulted in 
decreased intracellular recombinant protein expression. Gene expression analysis 
revealed that absence of RutR coordinates a decrease in the expression of carA, tRNA-
synthetases and some amino acid transporter genes. Although, these results suggest 
that the absence of functional RutR promotes the balance between translation and 
secretion by slowing the translation rate, the mechanism needs to be further 
investigated. Overall, these studies present a new target for metabolic engineering to 
enhance extracellular secretion via the Type-I pathway. More generally, the results  
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Table 6.3. mRNA fold change levels of tRNA-synthetase genes for proline, arginine, 
tyrosine and histidine in the Hly-ycdC- mutant relative to the Hly-ycdC+ strain. Values 
less than 1.0 indicate a lower expression level in the hly-ycdC- mutant and vice versa. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
tRNA-synthetase 
(gene name) 
Fold change  
(Hly-ycdC¯ / Hly-ycdC+) 
alaS 0.84 
argS 0.88 
asnS 0.97 
aspS 0.96 
cysS 0.76 
glnS 0.68 
gltX 0.83 
glyQ 0.72 
glyS 0.60 
hisS 0.72 
ileS 0.64 
leuS 0.71 
lysS 0.86 
lysU 0.98 
metG 0.66 
pheS 0.83 
pheT 0.86 
proS 0.58 
serS 1.01 
thrS 0.79 
trpS 0.94 
tyrS 0.84 
valS 0.68 
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reported here demonstrate the utility of short read genome sequencing technology to 
identify gene targets and genetic variations that can accelerate the development of 
novel organisms for biotechnology applications. 
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CHAPTER 7 
CONCLUSION AND FUTURE DIRECTIONS 
 
7.1 Summary 
The first part of this thesis highlighted the use of ‘directed silent mutagenesis’ to 
enhance recombinant protein secretion in Escherichia coli. This method incorporates 
synonymous rare codon clusters at specific sites in the target genes, based on the 
predictions by a previously developed mathematical model of translation [1]. A 
significant increase in the secretion of active HlyA protein via the Type-I pathway was 
observed and the effect of a synonymous rare codon cluster on HlyA secretion was 
studied in detail. Different factors (including mRNA expression, secretion machinery 
expression, protein degradation) were investigated that may account for the enhanced 
secretion phenotype and the data suggested that the observed phenotype is the result of 
decreased total HlyA protein production relative to the hly-parent strain. It was also 
shown that most of the intracellular HlyA exists in the inclusion body fraction. The 
results illustrated that production of high levels of secreted proteins appears to require 
a balance between translation and secretion rate. Synonymous rare codon engineering 
enhanced secretion of recombinant proteins not only via the Type-I pathway but also 
via other pathways (Sec, Tat, and HasABC).  
 
The secretion pathways were also used to study the effects of synonymous 
substitutions on protein folding. Type-I secretion studies suggested that the effects of 
synonymous mutations are protein specific and can affect the quality control 
mechanisms (protein aggregation, degradation) that are triggered by the 
overexpression of a recombinant protein. The studies of protein secretion via the Tat 
and the HasABC exporters strongly suggested that the presence of abnormal 
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translation kinetics, caused by the ribosome moving slower through the rare codon 
cluster, can alter the final protein conformation and activity.  It was also observed that 
synonymous rare codon substitutions can alter the interaction of a polypeptide with an 
unfolding/folding modulator. The association of a molecular chaperone (EF-Tu) with 
beta-lactamase protein tagged for secretion via the Type-I and the Tat pathways was 
discovered and it was hypothesized that EF-Tu might impede secretion by preventing 
the polypeptide to fold in the secretion-competent conformation. Based on these 
observations, the presence of secretion-competent and secretion-incompetent pools of 
polypeptides was suggested. It was also hypothesized that the introduction of rare 
codons in a specific stretch of the target gene can affect the balance of these pools and 
the secretion flux, since failure to rapidly reach a secretion competent conformation 
may either result in partial or complete deposition into insoluble aggregates or 
degradation. These results offer insights into the possible mechanisms of how silent 
mutations can affect protein structure and function.  
 
The second part of the thesis illustrated the use of ‘next-generation’ sequencing 
technology to profile the hypersecreter mutants, created by random mutagenesis. This 
work involved sequencing a previously isolated derivative hypersecreter E. coli strain 
(B41) [2] and parent strain using Illumina sequencing technology. Mutational 
profiling of B41 and parent genomes revealed a single nucleotide polymorphism (G  
T) in B41 genome, which results in premature translation termination of a 
transcription factor (RutR). Different factors that may account for the effect of the 
SNP on HlyA secretion phenotype were investigated and the data suggested that the 
absence of functional RutR resulted in decreased intracellular recombinant protein 
expression. Comparative gene expression analysis was also performed which revealed 
that absence of RutR coordinates a decrease in the expression of carA, tRNA-
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synthetases and some amino acid transporter genes. Although, these results suggest 
that the absence of functional RutR promotes the balance between translation and 
secretion by slowing the translation rate, the mechanism needs to be further 
investigated. These studies presented a single gene target to enhance extracellular 
secretion via the Type-I pathway and highlighted the potential of new high-throughput 
massively parallel sequencing technologies to characterize selected mutants for strain 
improvement. 
 
7.2 Recommendations for future work 
7.2.1 Quantitative understanding of the affect of synonymous rare codon cluster 
on protein secretion 
To predict the effect of synonymous rare codon cluster on protein secretion, it is 
important to understand the relationship between the type of rare codon used and the 
position of the rare codon cluster. Hence experiments need to be designed in such a 
way to decouple the two parameters and study their effect individually on secretion 
yield. I have observed from the experiments, with beta-lactamase (Bla) as the model 
protein, that there is a position-dependent effect of the incorporation of a rare codon 
cluster. In particular, we observed an increased secretion of Bla in a mutant strain 
containing the synonymous rare codon cluster near the 3’ end of the gene. This 
observation might be because of Bla folding change resulting in more secretion 
compatible protein. Further experiments can be performed to understand the codon 
specific effects of an interesting mutant (having an increased or a decreased secretion 
phenotype relative to the parent strain). In other words, different combinations of 
codon changes for a particular mutant of the model gene can be made and tested for 
secretion and intracellular protein expression. This kind of combinatorial approach 
will give some clues about the combinations of codon changes which are most 
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important for affecting the secretion yield for a particular position of the rare codon 
cluster. Similar experiments can be done for other model proteins and the data 
generated from these sets of experiments can be fed into the secretion model to obtain 
estimates on the rate parameters for protein aggregation and translation rate to better 
understand and predict the secretion behavior of various mutants for a given 
recombinant protein. This strategy would also help in designing mutant strains more 
objectively for a given protein.  
 
7.2.2 Study the effect of chaperone proteins on protein secretion 
In recombinant cells, proteolysis and aggregation can compete with each other and can 
be observed as antagonistic events for folding-reluctant proteins [3]. Since folding, 
aggregation and degradation are all competing processes, the protein processing step is 
very important in deciding the fate of the polypeptide, targeted for secretion. Both 
chaperones and proteases are components of the quality control system in the cell [4], 
devoted to surveying the folding status of cellular proteins. But it is not clear how the 
discrimination between folding attempts or proteolysis occurs [5] or if specific signals 
in target polypeptides are involved in deciding between both events. It has been 
reported in the literature that overexpression of aggregated protein can be minimized 
by controlling process parameters such as temperature, reducing recombinant gene 
expression, protein engineering or by the co-expression of plasmid encoded chaperone 
genes [3]. To minimize the amount of aggregate formation in the system and direct 
more protein towards secretion, the effect of chaperones on the secretion capacity can 
be explored. Recently, it has been argued that GroEL is involved in both the protein 
removal from the inclusion bodies as well as in the promotion of inclusion body 
formation in bacteria by clustering of small aggregated nuclei [6]. Hence it will be 
interesting to explore the effects of over-expression and deletion of some key 
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chaperones on the secretion of model proteins. Secretion studies of a “slow” mutant 
and parent strain for at least two model proteins can be performed in two types of 
strains; one with a GroEL(-)  background and one in which GroEL and GroES are 
being co-expressed on a plasmid vector. The GroEL(-) strain can be created using 
standard gene knockout techniques (e.g. homologous recombination). For further 
analysis, similar studies on the DnaK chaperone can be performed. 
  
7.2.3 Creation of synonymous codon library  
I observed from my studies that the presence of a synonymous rare codon cluster can 
affect the folding of the polypeptide. This observation adds evidence to the growing 
literature that silent mutations can change protein structure and function [7,8,9] and 
challenges the general notion that protein evolution occurs only by changes in the 
primary amino acid sequence. In order to further validate that protein folding may be 
nucleotide sequence dependent, a synonymous rare codon library of a reporter protein 
(e.g. green fluorescent protein) can be created, which would consist of gene sequences 
having different nucleotides but encoding the same amino acid sequence. This may be 
achieved by using semi-randomized weighted oligonucleotide synthesis and end-to-
end ligation [10]. The library will be semi-randomized because only the third base of 
the codons will be randomized in order to achieve the same amino acid sequence. The 
synonymous library can also be fused with an N-terminal signal sequence (ssTorA) for 
secretion via the Tat pathway. This experiment can be used to detect the “super-
folders” and the “poor-folders” because the Tat pathway has an inherent quality 
control mechanism and secretes only the folded polypeptides [11,12]. Once an 
interesting mutant is discovered, biophysical characterization can be performed to link 
the changes in the gene sequence to the changes in the secondary structure.  
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7.2.4 Exploring the mechanism of RutR protein for enhanced secretion 
The studies involving genome sequence comparison of B41 and parent genome 
revealed that the absence of functional RutR can result in enhanced secretion of 
recombinant proteins via the Type-I secretion pathway. The study hypothesized that 
RutR might affect the balance between different substrates of the translation 
machinery in E. coli, thereby affecting the translation rate of all proteins and in 
particular, the recombinant protein of interest. An intracellular free-amino acid 
quantitation can be performed to test this hypothesis. Additionally, the data indicates 
decreased expression of carA gene in the B41 strain, consistent with the idea that 
CarAB protein might also be an important player in the RutR mediated translation 
regulation. Hence, secretion and intracellular protein studies can be performed in a 
carA deletion mutant. Also, RutR effect and synonymous rare codon cluster effect 
may be simultaneously studied by transforming hly-slow and other mutants into the 
ycdC deletion background. The expectation is that the combined effect may slow 
down the translation of the recombinant protein even further and may result in higher 
secretion yields.  
 
7.3 Conclusion 
The work presented here includes different type of strategies to improve protein 
secretion in E. coli. A directed silent mutagenesis approach illustrates the utility of 
synonymous rare codon engineering to improve recombinant protein secretion via 
multiple secretion pathways for bioprocess applications. These studies also reveal that 
the incorporation of synonymous rare codon clusters at specific sites can modulate the 
interactions with specific molecular chaperones and can drive the in vivo folding of the 
polypeptide chain into different conformations. This research not only opens up a new 
avenue to study the effect of silent mutations on protein folding/misfolding, but also 
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suggest that silent single nucleotide polymorphisms (SNPs) should not be neglected in 
determining the likelihood of the development and progression of many diseases such 
as Alzheimer’s disease and others that are strongly linked to SNPs [13]. I also used 
‘next-generation’ sequencing technologies in tandem with genomic expression 
analysis to characterize selected mutants leading to successful metabolic engineering 
strategies for strain improvement. These studies not only presents a single gene target 
in E. coli to enhance the extracellular secretion of recombinant proteins, but also 
illustrate the promise of genome sequencing towards rational design of interesting 
phenotypes for biotechnology applications.  
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APPENDIX A 
 
A.1 Effect of temperature on HlyA secretion by the Type-I pathway  
We observed from our studies that a decreased intracellular HlyA aggregate 
formation, as a result of synonymous rare codon cluster, can result in enhanced active 
HlyA secretion. Previous studies have observed that lowering the culture temperature 
can slow down the translation rate. Hence, we tested if a decrease in culture 
temperature can affect the secretion yield of active HlyA protein. HlyA secreting cells 
were grown at 37 °C and 30 °C. Supernatant fractions were analyzed for active HlyA 
using liquid blood lysis assay. The results indicated that cells grown at 37 °C secrete 
nearly 2.6-fold more active HlyA relative to the cells grown at 30 °C (Fig. A.1). This 
observation indicates that lower temperature might exert some other effects on the 
Type-I secretion system and needs to be further evaluated. 
 
 A.2. Positional effects of the rare codon cluster on Bla secretion via the Sec and 
Tat pathways 
Positional effects of the synonymous rare codon cluster on Bla secretion by the Sec 
and Tat pathways were investigated. The de novo gene sequence (Fig. 5.7) was used 
for these experiments. Synonymous mutants are synthesized by replacing the new  
codon cluster with the ‘rare’ codon cluster (GGG ATA CTA CTA) at each position 
(Table A.1). Quantitative western analysis of the periplasmic fractions indicated that 
Sec strains secrete significantly less GILL-Bla protein (Fig. A.2). We also observed 
that there is a significant decrease in the cytoplasmic GILL-Bla expression in the Sec-
M3 mutants (Fig. A.2). The observations suggest that GILL-Bla protein expressed 
with a Sec signal peptide attains a conformation, which is secretion inhibitory. For the  
Tat pathway, quantitative western analysis indicated a 2-fold increase in secretion in 
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Figure A.1. Liquid blood lysis assay to quantify the amount of secreted active HlyA 
protein in the cells grown at 37 °C and 30 °C. Each reading was performed in 
triplicates and error bars show the standard deviation of triplicate measurements. The 
supernatant dilution corresponding to 50% hemolysis was calculated (numbers in bold 
marked by blue dashed arrows) from the lysis curve and secretion fold change was 
calculated by taking the ratio of the dilutions. 
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Table A.1. Sequence changes (marked in red) and predicted % decrease in translation 
rate of different sec-bla and tat-bla mutants   
 
 
(b) GILL-
Sec-Bla 
Mutants 
Sequence % 
predicted 
Slowdown 
 
gillsecM1 
 
210  AAAGGTA TCCTGCTGTG T  initial sequence    
     AAAGGGA TACTACTATG T  rare codon seq. 
 70  K  G  I   L  L  C     amino acid seq.    
 
 
5.3% 
gillsecM2 402  AACGGTA TCCTGCTGAC A  initial sequence    
     AACGGGA TACTACTAAC A  rare codon seq. 
134  N  G  I   L  L  T     amino acid seq. 
 
19% 
gillsecM3 726  CGCGGTA TCCTGCTGGC A  initial sequence    
     CGCGGGA TACTACTAGC A  rare codon seq. 
242  R  G  I   L  L  A     amino acid seq. 
10.6% 
 
 
 
 
 
 
(b) GILL-
Tat-Bla 
Mutants 
Sequence % 
predicted 
Slowdown 
 
gilltatM1 
 
297  AAAGGTA TCCTGCTGTG T  initial sequence    
     AAAGGGA TACTACTATG T  rare codon seq. 
 99  K  G  I   L  L  C     amino acid seq.    
 
 
5.3% 
gilltatM2 558  AACGGTA TCCTGCTGAC A  initial sequence    
     AACGGGA TACTACTAAC A  rare codon seq. 
186  N  G  I   L  L  T     amino acid seq. 
 
19% 
gilltatM3 882  CGCGGTA TCCTGCTGGC A  initial sequence    
     CGCGGGA TACTACTAGC A  rare codon seq. 
294  R  G  I   L  L  A     amino acid seq. 
    10.6%   
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Figure A.2. Positional effect of rare codon cluster on Bla secretion by the Sec 
pathway. Normalized Western analysis of Bla in (a) periplasmic fraction (peri), and 
(b) cytoplasmic fraction (cyto). An equivalent number of cells were harvested. P & M 
are precursor and mature form of Bla. 
Bla peri
cytoBla
Sec-W    Sec- M1    Sec-M2    Sec-M3
Sec-W    Sec- M1  Sec-M2  Sec-M3
a
b
GILL       GILL GILL GILL
GILL       GILL GILL GILL
P
M
P
M
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GILL-Tat-M1 strain relative to GILL-Tat-W parent strain (Fig. A.3). However, 
significant decrease in secretion was observed for the other two strains relative to the 
parent strain. The GILL-Tat-M3 strain has a 60% decrease in GILL-Bla intracellular 
expression (Fig. A.3).The results suggest that the presence of the synonymous rare 
codon cluster near the 5’end can facilitate GILL-Bla secretion via the Tat pathway. 
However, the cluster near the 3’end severely affects its ability to fold into a secretion 
competent conformation. 
 
A.3. Bla secretion by the Sec and Tat pathways in a ycdC::Tn5 background 
It was observed from our experiments that there is an enhanced secretion of α-
hemolysin and Bla protein by the Type-I pathway in ycdC::Tn5 background. The 
effect of a non-functional RutR on Bla secretion by the Sec and the Tat pathways was 
also investigated. The results of Bla secretion by the Sec pathway indicated no bla 
secretion in the periplasmic fraction of both the parent and ycdC- strains (Fig. A.4). 
Faint Bla bands were observed in the cytoplasmic fractions of the two strains, 
suggesting that either the intracellular Bla was aggregated or degraded (Fig. A.4). A 
relatively dark band was observed in both the periplasmic and cytoplasmic fractions at 
around 55 kDa, suggesting the presence of Bla dimers (Fig. A.4). The absence of Bla 
secretion by the Sec pathway may be a strain dependent effect, since MG1655 strain 
was used in these experiments. Bla protein was to secrete relatively well by the Tat 
pathway in both the parent and ycdC- strains; however there was no relative difference 
in the band intensities (Fig. A.5). Moreover, most of the Bla protein present in the 
periplasmic fraction contained precursor Bla. No difference was observed in the 
cytoplasmic fractions of the two strains as well (Fig. A.5).  
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Figure A.3. Positional effect of rare codon cluster on Bla secretion by the Tat pathway. 
Normalized Western analysis of Bla in (a) periplasmic fraction (peri), and (b) 
cytoplasmic fraction (cyto). An equivalent number of cells were harvested.  
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cyto
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Figure A.4. Bla secretion by the Sec pathway in ycdC::Tn5 background. Normalized 
Western analysis of Bla in (a) periplasmic fraction (peri), and (b) cytoplasmic fraction 
(cyto). An equivalent number of cells were harvested 
Parent    ycdC-
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peri
cyto
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b
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Figure A.5. Bla secretion by the Tat pathway in ycdC::Tn5 background. Normalized 
Western analysis of Bla in (a) periplasmic fraction, and (b) cytoplasmic fraction. An 
equivalent number of cells were harvested. P & M are precursor and mature form of 
Bla.  
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